<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="other">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">SCV</journal-id>
<journal-id journal-id-type="hwp">spscv</journal-id>
<journal-id journal-id-type="nlm-ta">Semin Cardiothorac Vasc Anesth</journal-id>
<journal-title>Seminars in Cardiothoracic and Vascular Anesthesia</journal-title>
<issn pub-type="ppub">1089-2532</issn>
<issn pub-type="epub">1940-5596</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1089253211434966</article-id>
<article-id pub-id-type="publisher-id">10.1177_1089253211434966</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Reviews</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Management of the Patient for Transcatheter Aortic Valve Implantation in the Perioperative Period</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Huffmyer</surname><given-names>Julie</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-1089253211434966">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Tashjian</surname><given-names>Jessica</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-1089253211434966">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Raphael</surname><given-names>Jacob</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-1089253211434966">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Jaeger</surname><given-names>J. Michael</given-names></name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff1-1089253211434966">1</xref>
</contrib>
</contrib-group>
<aff id="aff1-1089253211434966"><label>1</label>University of Virginia, Charlottesville, VA, USA</aff>
<author-notes>
<corresp id="corresp1-1089253211434966">Julie Huffmyer, University of Virginia, PO Box 800710, Charlottesville, VA 22908-0710, USA Email: <email>jh3wd@virginia.edu</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>3</month>
<year>2012</year>
</pub-date>
<volume>16</volume>
<issue>1</issue>
<fpage>25</fpage>
<lpage>40</lpage>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Aortic stenosis is a prevalent valvular disease among aging patients, and surgical correction is the most definitive treatment. Yet many elderly patients are deemed to be “inoperable” or at excessive risk to undergo open surgical aortic valve replacement (AVR). Transcatheter aortic valve implantation (TAVI), either through a transfemoral or transapical approach, has become a potential option for these high-risk patients. Although TAVI technology will continue to be developed and perfected, most studies at this time reveal that symptoms are improved and that 1-year morbidity and mortality are similar to those for open surgical AVR. Anesthetic management for patients undergoing TAVI involves maintaining hemodynamic stability during periods of rapidly changing conditions and providing echocardiographic guidance and assessment. Postoperative care includes a variety of challenges such as managing pain control, monitoring for potential complications, and providing hemodynamic management.</p>
</abstract>
</article-meta>
</front>
<body>
<sec id="section1-1089253211434966" sec-type="intro">
<title>Introduction</title>
<p>Aortic stenosis (AS) is the most prevalent form of valvular heart disease. Valvular calcification is the most common etiology of AS, particularly among aging patients. The incidence among patients older than 65 has been estimated at 2%, with those older than 85 years having a 4% incidence of AS.<sup><xref ref-type="bibr" rid="bibr1-1089253211434966">1</xref></sup> Accordingly, the incidence of senile calcific AS is expected to increase as the population continues to age. Calcific AS generally progresses such that the aortic valve area is reduced by 0.1 cm<sup>2</sup>/year, and the aortic blood flow velocity increases by 0.3 m/s/year with an increase in mean aortic gradient of 7 mm Hg/year.<sup><xref ref-type="bibr" rid="bibr2-1089253211434966">2</xref></sup> Patients are often asymptomatic or do not recognize significant symptoms until late in the disease progression. Once the classic symptoms of angina, syncope, and dyspnea develop, the average survival without intervention is 5, 3, and 2 years, respectively.<sup><xref ref-type="bibr" rid="bibr3-1089253211434966">3</xref>,<xref ref-type="bibr" rid="bibr4-1089253211434966">4</xref></sup> Conservative medical treatment of AS, including the use of ACE inhibitors to decrease disease-related events and statin therapy to decrease the inflammatory component of AS,<sup><xref ref-type="bibr" rid="bibr5-1089253211434966">5</xref>,<xref ref-type="bibr" rid="bibr6-1089253211434966">6</xref></sup> has failed to slow disease progression. A recent retrospective cohort study found that patients with severe AS who were conservatively treated (no AVR) had survival at 1, 5, and 10 years of 62%, 32%, and 18%, respectively.<sup><xref ref-type="bibr" rid="bibr7-1089253211434966">7</xref></sup></p>
<p>The timing of aortic valve replacement (AVR) is largely dependent on symptoms. Classically, angina, syncope, and congestive heart failure or dyspnea portend increased disease severity and indicate need for replacement of the aortic valve.<sup><xref ref-type="bibr" rid="bibr8-1089253211434966">8</xref></sup> Severe AS is characterized by a valve area of &lt;1.0 cm<sup>2</sup>, mean gradient &gt;40 mm Hg, or aortic jet velocity &gt;4.0 m/s.<sup><xref ref-type="bibr" rid="bibr9-1089253211434966">9</xref>,<xref ref-type="bibr" rid="bibr10-1089253211434966">10</xref></sup> Both severe AS in a symptomatic patient or left ventricular (LV) systolic dysfunction are considered class I indications for AVR. Asymptomatic severe AS with an abnormal response to exercise is considered a class IIB indication for surgical intervention.</p>
</sec>
<sec id="section2-1089253211434966">
<title>Treatment Options</title>
<p>Open surgical AVR is associated with morbidity and mortality, especially for elderly patients with significant medical comorbidities. As the number of patients with severe AS increases, medical professionals are challenged to create therapeutic innovations that provide improved quality of life for patients with comorbidities that preclude open repair. First described in 2002, transcatheter aortic valve implantation (TAVI) has become one such option for patients considered high risk for traditional open surgical procedures.<sup><xref ref-type="bibr" rid="bibr11-1089253211434966">11</xref></sup> The implementation of transcatheter techniques for AVR has necessitated the development of multidisciplinary teams, including interventional cardiologists, cardiothoracic surgeons, anesthesiologists, perfusionists, cardiac catheterization laboratory personnel, and operating room personnel such as circulating nurses and surgical technicians.</p>
<p>Determining whether a patient should undergo conventional open surgical AVR versus TAVI involves weighing the risks of both procedures. Evaluation of cardiac surgical risk has been done with numerous scoring systems, the most prevalent of which are EuroSCORE and the Society of Thoracic Surgeons Predicted Risk of Mortality (STS-PROM) algorithms.<sup><xref ref-type="bibr" rid="bibr12-1089253211434966">12</xref>,<xref ref-type="bibr" rid="bibr13-1089253211434966">13</xref></sup> Common variables exist between these 2 algorithms, including age, sex, presence of pulmonary and renal disease, peripheral vascular disease, previous cardiac surgery, and the preoperative state of the patient. Some authors have expressed concern that current scoring systems may not provide accurate estimates of mortality, particularly for high-risk patients.<sup><xref ref-type="bibr" rid="bibr14-1089253211434966">14</xref>,<xref ref-type="bibr" rid="bibr15-1089253211434966">15</xref></sup> Several groups have studied the scoring algorithms and the STS-PROM algorithm was determined to provide the closest estimate of actual observed 30-day mortality, although it did slightly underestimate mortality.<sup><xref ref-type="bibr" rid="bibr16-1089253211434966">16</xref>,<xref ref-type="bibr" rid="bibr17-1089253211434966">17</xref></sup> Current ongoing transcatheter trials involve patients deemed as being “inoperable,” with an unacceptably high operative risk or patients with STS-PROM score &gt;10 or predicted mortality &gt;15%.<sup><xref ref-type="bibr" rid="bibr18-1089253211434966">18</xref></sup></p>
<p>Currently, 2 different mechanical transcatheter aortic valves are commercially available. The devices, in general, consist of a bioprosthetic valve seated inside a vascular stent. The majority of studies in the United States involve the balloon-expandable Edwards SAPIEN Valve (Edwards Lifesciences Inc, Irvine, CA), but Medtronic’s self-expanding CoreValve (Medtronic Inc, Minneapolis, MN) will soon begin to be evaluated as well. Differences in sheath size and the mechanism of deployment will likely result in potentially different risk profiles for these devices. A randomized trial to evaluate the TAVI outcomes is the Placement of Aortic Transcatheter Valves (PARTNER) trial, using the Edwards SAPIEN valve, the first arm results of which was published in 2010.<sup><xref ref-type="bibr" rid="bibr19-1089253211434966">19</xref></sup> Patients who were not surgical candidates were randomized to either conservative treatment or TAVI. Those patients treated with the TAVI approach had improved quality of life, reduced symptoms, and an increase of 20% in the 1-year survival rate. Another PARTNER trial in the United States, recently published in 2011, compared open surgical AVR versus TAVI in patients deemed to be high risk for surgical intervention.<sup><xref ref-type="bibr" rid="bibr20-1089253211434966">20</xref></sup> At 1 month after AVR, the surgical group had increased adverse events such as bleeding and new onset atrial fibrillation, whereas the transcatheter group had significantly increased risk of vascular complications.<sup><xref ref-type="bibr" rid="bibr20-1089253211434966">20</xref></sup> There was no significant difference in stroke between the groups at 30 days or 1 year.<sup><xref ref-type="bibr" rid="bibr20-1089253211434966">20</xref></sup> Symptom improvement was significantly greater in the TAVI group at 30 days as compared with the surgical group, but that difference was not significant at 1 year.<sup><xref ref-type="bibr" rid="bibr20-1089253211434966">20</xref></sup> As the PARTNER trial continues, newer devices with smaller access sheaths are being used, and in addition, patients who are lower surgical risk are being evaluated for long-term outcomes.</p>
<p>The Edwards SAPIEN valve is a pericardial tissue valve, hand sewn to a stainless steel, balloon-expandable stent (<xref ref-type="fig" rid="fig1-1089253211434966">Figures 1</xref> and <xref ref-type="fig" rid="fig2-1089253211434966">2</xref>). The SAPIEN valve can be implanted via either a transfemoral or transapical approach. The CoreValve system (<xref ref-type="fig" rid="fig3-1089253211434966">Figure 3</xref>) is a tissue valve mounted on a self-expanding nitinol frame that has been used primarily in Europe for several years and has recently started to be evaluated in the United States.<sup><xref ref-type="bibr" rid="bibr21-1089253211434966">21</xref></sup> A study based in France compared the use of Edwards SAPIEN TAVI versus the CoreValve and found that the only significant difference was the increased rate of pacemaker implantation for patients with the CoreValve, thought to be a result of a deeper intraventricular insertion of the CoreValve into the area of the noncoronary cusp of the aortic valve.<sup><xref ref-type="bibr" rid="bibr22-1089253211434966">22</xref></sup> The authors report 1 advantage of the CoreValve to be a smaller introducer size for the transfemoral approach, allowing it to be used in patients with smaller femoral vasculature.<sup><xref ref-type="bibr" rid="bibr22-1089253211434966">22</xref></sup></p>
<fig id="fig1-1089253211434966" position="float">
<label>Figure 1.</label>
<caption>
<p>Edwards SAPIEN XT valve (with permission from Edwards Lifesciences, Inc)</p>
</caption>
<graphic xlink:href="10.1177_1089253211434966-fig1.tif"/></fig>
<fig id="fig2-1089253211434966" position="float">
<label>Figure 2.</label>
<caption>
<p>SAPIEN valve during deployment (with permission from Edwards Lifesciences, Inc)</p>
</caption>
<graphic xlink:href="10.1177_1089253211434966-fig2.tif"/></fig>
<fig id="fig3-1089253211434966" position="float">
<label>Figure 3.</label>
<caption>
<p>Image of the Medtronic CoreValve system provided by Medtronic, Inc; the Medtronic CoreValve system is currently limited to investigational use in the United States</p>
</caption>
<graphic xlink:href="10.1177_1089253211434966-fig3.tif"/></fig>
</sec>
<sec id="section3-1089253211434966">
<title>Preoperative Evaluation and Preparation</title>
<p>In the preoperative period, the patient presenting for TAVI should be evaluated and prepared as any patient with severe AS. A thorough history should be undertaken, with attention paid to significant comorbidities such as cerebrovascular disease, preexisting renal insufficiency, cardiac rhythm disturbances, and pulmonary disease. As atrial fibrillation is a common comorbidity in elderly patients with AS, Coumadin is a medication that requires preoperative discontinuation to reduce bleeding risk at the time of TAVI. Patients are usually instructed to stop their Coumadin approximately 1 week prior to the procedure and may be bridged to the day of surgery with heparin. A preoperative echocardiogram should be available with an estimation of LV ejection fraction in addition to evaluation of the consequences of severe AS such as concentric LV hypertrophy, impaired relaxation of the LV, and pulmonary hypertension. Recent coronary, aortoiliac, and femoral angiography should be reviewed to evaluate for coexistent coronary artery disease, vascular disease, and patency of femoral access vessels. The usual preanesthetic evaluation should be conducted, including assessment of the airway and physical examination, and the patient should be educated regarding the anesthetic plan, including invasive vascular access placement and expectations for postoperative care, which should include ICU destination and pain control options. The hybrid suite should be prepared in a manner similar to the cardiac operating room.</p>
<p>Many of the patients who are candidates for TAVI have unacceptably high surgical risk, making them “inoperable” by usual standards. An important part of the preoperative interview and planning process is to discuss the management of unexpected cardiac arrest during induction of anesthesia or throughout the TAVI procedure. Centers performing TAVI will have perfusionist and cardiopulmonary bypass (CPB) backup throughout the case, so that urgently instituting CPB is a viable option. The quickest vascular access to obtain if CPB becomes urgently necessary is percutaneous femoral arterial and venous access for bypass cannulae. Regardless of the ease of access to CPB support, if a patient with severe AS sustains cardiac arrest and requires cardiopulmonary resuscitation in the process of TAVI, it may be very difficult to restore a normal, perfusing heart rhythm and cardiac function.</p>
</sec>
<sec id="section4-1089253211434966">
<title>Intraoperative Period</title>
<sec id="section5-1089253211434966">
<title>Surgical Approach</title>
<p>Transcatheter valve replacement is possible via either the femoral artery or the LV apex. The anatomy of these regions largely determines the approach; for example, tortuous iliac arteries, extensive peripheral vascular disease, or prolific aortic atheroma will likely preclude a transfemoral approach. Similarly, apical aneurysm, pericardial disease, or a history suggestive of left thoracic adhesions make left minithoracotomy and LV apical cannulation less attractive. <xref ref-type="table" rid="table1-1089253211434966">Table 1</xref> describes the various pros and cons inherent to each approach; most preliminary reports do not suggest a major difference in mortality between the 2 procedures.<sup><xref ref-type="bibr" rid="bibr23-1089253211434966">23</xref>-<xref ref-type="bibr" rid="bibr25-1089253211434966">25</xref></sup></p>
<table-wrap id="table1-1089253211434966" position="float">
<label>Table 1.</label>
<caption>
<p>Pros and Cons of Different Surgical Approaches for TAVI</p>
</caption>
<graphic alternate-form-of="table1-1089253211434966" xlink:href="10.1177_1089253211434966-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center">Transfemoral</th>
<th align="center">Transapical</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pros</td>
<td><list list-type="bullet">
<list-item><p>Access percutaneous; femoral cut-down may be required</p></list-item>
</list></td>
<td>
<list list-type="bullet">
<list-item><p>Easier to position valve</p></list-item>
<list-item><p>Can be accomplished in patients with vascular disease, aortic pathology</p></list-item>
</list></td>
</tr>
<tr>
<td>Cons</td>
<td><list list-type="bullet">
<list-item><p>High risk of vascular damage, especially with larger sheaths</p></list-item>
<list-item><p>More difficult to position valve</p></list-item>
</list></td>
<td><list list-type="bullet">
<list-item><p>Apical incision difficult to close</p></list-item>
<list-item><p>Increased postoperative pain secondary to minithoracotomy</p></list-item>
<list-item><p>Position of heart may require lung isolation and 1-lung ventilation for apical access</p></list-item>
<list-item><p>Higher incidence of ectopy</p></list-item>
<list-item><p>Sheath may impede CO (especially in patients with LVH)</p></list-item>
</list></td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1089253211434966">
<p>Abbreviations: TAVI, transcatheter aortic valve implantation; CO, cardiac output; LVH, left ventricular hypertrophy.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>These procedures are usually performed in a hybrid cardiac catheterization laboratory/operating room with capability for fluoroscopy, open surgical techniques, and CPB. The need for CPB in these patients may result from an inability to tolerate the hemodynamic instability inherent for the procedure because of rapid ventricular pacing (RVP; see below) or secondary to a complication such as valve embolism, LV rupture, or aortic dissection. The preprocedural strategy should be discussed between the interventional cardiologist, cardiac surgeon, perfusionist, and anesthesiologist to include planning for placement of bypass cannulae and for alternative approaches if there is vascular injury or other complication.</p>
</sec>
<sec id="section6-1089253211434966">
<title>Basic Steps of TAVI</title>
<p>The basic steps of the surgical process of both transfemoral and transapical TAVI are given in <xref ref-type="table" rid="table2-1089253211434966">Table 2</xref>. Once the patient is anesthetized and arterial and venous access is accomplished, the interventional cardiology and surgical teams obtain femoral venous and arterial access for possible CPB cannulation and also prepare the transapical patient by performing a left minithoracotomy. Occasionally, if femoral access is difficult, other plans may be required for CPB cannulation, such as exposing the axillary vessels. Once the access is accomplished to the aortic valve (by either the transfemoral or transapical route), RVP to a heart rate of approximately 200 beats per minute is tested. Hemodynamic concerns regarding RVP are reviewed in the anesthesia management section to follow. Then, balloon aortic valvuloplasty is used to open the native, calcified aortic valve to prepare it for the placement of the new prosthesis (<xref ref-type="fig" rid="fig4-1089253211434966">Figure 4</xref>). The stented valve is then positioned at the level of the aortic annulus with the assistance of fluoroscopy and transesophageal echocardiography (TEE), and deployment of the prosthetic apparatus is undertaken. <xref ref-type="fig" rid="fig5-1089253211434966">Figure 5</xref> shows the stented valve prosthesis in place. Between RVP runs, the patient is allowed to recover, and hemodynamic stability is achieved. After TAVI placement, TEE and angiography are used to assess valve position, function, and aortic regurgitant jets. After satisfactory positioning is confirmed, the access sheaths are removed, angiography is again used to make sure the femoral vasculature has not been damaged, and incisions are closed.</p>
<table-wrap id="table2-1089253211434966" position="float">
<label>Table 2.</label>
<caption>
<p>Basic Steps of TAVI: Transfemoral and Transapical</p>
</caption>
<graphic alternate-form-of="table2-1089253211434966" xlink:href="10.1177_1089253211434966-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">Transfemoral<sup><xref ref-type="bibr" rid="bibr2-1089253211434966">2</xref></sup></th>
<th align="center">Transapical<sup><xref ref-type="bibr" rid="bibr27-1089253211434966">27</xref></sup></th>
</tr>
</thead>
<tbody>
<tr>
<td>Sheaths placed in femoral artery and vein; femoral incision if necessary</td>
<td>Sheaths placed in femoral artery and vein; surgical mini–left thoracotomy incision</td>
</tr>
<tr>
<td>Pacing wire placed in RV; capture is assured</td>
<td>Pacing wire placed in RV, capture is assured</td>
</tr>
<tr>
<td>Aortic valve is crossed with wire, then into LV</td>
<td>Direct puncture and sheath insertion into LV apex</td>
</tr>
<tr>
<td>RVP</td>
<td>Guidewire across aortic valve, into ascending aorta</td>
</tr>
<tr>
<td>Balloon aortic valvuloplasty</td>
<td>RVP</td>
</tr>
<tr>
<td>Recovery</td>
<td>Balloon aortic valvuloplasty</td>
</tr>
<tr>
<td>RVP</td>
<td>Recovery</td>
</tr>
<tr>
<td>Stent and valve deployment</td>
<td>RVP</td>
</tr>
<tr>
<td>Recovery, assessment of AR jets, malposition, embolization, ECG changes</td>
<td>Stent and valve deployment</td>
</tr>
<tr>
<td>Angiography to ensure patency of vasculature and hemostasis</td>
<td>Recovery, assessment of AR jets, malposition, embolization, ECG changes</td>
</tr>
<tr>
<td>Vascular closure device, surgical closure if femoral site cut down was used</td>
<td>Closure of surgical incision</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-1089253211434966">
<p>Abbreviations: TAVI, transcatheter aortic valve implantation; RV, right ventricle; LV, left ventricle; RVP, rapid ventricular pacing; AR, aortic regurgitation; ECG, electrocardiography.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<fig id="fig4-1089253211434966" position="float">
<label>Figure 4.</label>
<caption>
<p>Balloon aortic valvuloplasty</p>
</caption>
<graphic xlink:href="10.1177_1089253211434966-fig4.tif"/></fig>
<fig id="fig5-1089253211434966" position="float">
<label>Figure 5.</label>
<caption>
<p>Stented aortic valve prosthesis</p>
</caption>
<graphic xlink:href="10.1177_1089253211434966-fig5.tif"/></fig>
</sec>
<sec id="section7-1089253211434966">
<title>Anesthetic Plan and Considerations</title>
<p>Both general anesthesia and sedation have been described as anesthetic options for TAVI. Sedation is thought to be feasible for the transfemoral approach only; however, there is a case report of thoracic epidural anesthesia being used for a transapical approach.<sup><xref ref-type="bibr" rid="bibr28-1089253211434966">28</xref></sup> Advantages of sedation include avoiding the hemodynamic compromise that may be associated with general anesthesia and positive-pressure ventilation, presumed faster recovery time, and the ability to clinically assess neurological status.<sup><xref ref-type="bibr" rid="bibr29-1089253211434966">29</xref></sup> In the United States, most TAVIs are done under general anesthesia to minimize patient movement, to be prepared with rapid airway control for the possible institution of CPB, and to facilitate the use of TEE for evaluation of stent and valve positioning.</p>
<p>Goals of anesthesia induction and maintenance for patients undergoing TAVI focus on optimization of hemodynamic stability in the face of severe AS. This includes maintaining preload; avoiding tachycardia and profound bradycardia, such that diastolic filling time is optimized but cardiac output is maintained; maintaining contractility; and maintaining afterload to maximize coronary perfusion. In addition to standard American society of anesthesiologists (ASA) monitors and external defibrillator pad placement, a preinduction radial arterial catheter is usually placed in the left radial artery for blood sampling and also to preserve right radial artery patency for possible cannulation by the interventional cardiology team. After induction, large-bore central venous access with pulmonary artery catheterization is accomplished for titration of vasopressors, inotropes, and volume administration in case of a vascular complication. Pulmonary artery catheter monitoring includes assessment of pulmonary arterial blood pressures as well as pulmonary capillary wedge pressures and the ability to monitor thermodilution cardiac output. In patients with severe AS with significantly impaired LV relaxation and coexistent pulmonary hypertension, these measurements may be helpful in the titration of vasoactive medications, both during the TAVI procedure and in the postoperative ICU. There is no single anesthetic agent of choice for TAVI, but the anesthetic plan should be tailored to each individual patient, with the goal of early extubation and fast-track ICU management. At the time of vascular sheath placement, anticoagulation is achieved with a heparin dose of 100 units/kg body weight. Additional heparin bolus is readily available in case of urgent institution of CPB. At the conclusion of the TAVI procedure, once wires and sheaths are withdrawn, heparin is reversed with protamine sulfate.</p>
<p>Intraoperatively, patients undergoing TAVI may be challenging to manage from many perspectives secondary to medical comorbidities. However, the periods of RVP provide the greatest source of hemodynamic instability. RVP is used to provide a reduction in ventricular ejection and cardiac motion in order to facilitate balloon valvuloplasty and subsequent valve deployment, thus decreasing the risk of valve embolization and malposition. By necessity, periods without ventricular ejection lead to hypotension of varying degrees. For patients with preserved ejection fraction, these times may be well tolerated with a quick recovery of blood pressure and cardiac output. In contrast, this is rarely the case for tenuous patients with a lower ejection fraction or cardiomyopathy, and accordingly, inotropic support, vasopressor administration, volume resuscitation, or CPB institution may be required. In our experience, testing pacing wire capture provides an excellent preview of how each patient will tolerate subsequent RVP.</p>
<p>After the procedure is completed and the incisions are closed, extubation is considered on a case-by-case basis. If the procedure has been uncomplicated and the patient does not require inotropic or vasopressor support and pain is well controlled, extubation may be an option in the hybrid operating room. Patients undergoing transapical TAVI usually have significantly more discomfort, and in our institution, these patients are transferred intubated with short-acting sedation to the ICU setting. Once stabilized from a coagulation and hemodynamic standpoint, transapical TAVI patients in our practice undergo paravertebral blocks for pain control and then are usually quickly extubated. Transfemoral and transapical TAVI patients are both monitored postoperatively in the ICU. If a TAVI patient has a history of atrial fibrillation or is at risk for thromboembolism and was on preoperative warfarin, the warfarin will need to be restarted after TAVI, once bleeding is controlled. It is customary for warfarin to be started and the patient maintained on heparin infusion until the warfarin dose reaches therapeutic levels.</p>
</sec>
<sec id="section8-1089253211434966">
<title>Transesophageal Echocardiography</title>
<p>TEE is used in most centers in the United States for TAVI patients to evaluate the native aortic annulus for sizing the aortic valve prosthesis, to examine the aorta for atheromatous disease, to evaluate LV function, and to assess for other pathologies such as mitral regurgitation (<xref ref-type="fig" rid="fig6-1089253211434966">Figure 6</xref>). An intraoperative baseline TEE exam includes several standard views to evaluate the native aortic valve and preoperative myocardial function (<xref ref-type="table" rid="table3-1089253211434966">Table 3</xref>). In addition, TEE is useful during the procedure to assist with placement of the guidewire and balloon for the balloon angioplasty and eventual stent placement across the native aortic valve (<xref ref-type="fig" rid="fig7-1089253211434966">Figures 7</xref> and <xref ref-type="fig" rid="fig8-1089253211434966">8</xref>). Intraoperative TEE is a valuable asset in the assessment of valve positioning after placement and especially in visualizing paravalvular or intravalvular aortic regurgitant jets. Other rare complications such as aortic dissection, rupture, coronary artery obstruction, and cardiac tamponade may also be assessed using TEE (<xref ref-type="fig" rid="fig9-1089253211434966">Figure 9</xref>). <xref ref-type="table" rid="table3-1089253211434966">Table 3</xref> reviews the basic TEE views used for TAVI patients. A recent study by Bagur and colleagues evaluated the use of TEE and angiography for patients undergoing transapical AVR and found that there was significantly less contrast used in the TEE group, but no significant difference was noted in procedural success, valve malposition, embolization, or survival.<sup><xref ref-type="bibr" rid="bibr30-1089253211434966">30</xref></sup></p>
<fig id="fig6-1089253211434966" position="float">
<label>Figure 6.</label>
<caption>
<p>TEE midesophageal aortic valve long-axis view; measurement of aortic annular diameter and sinotubular junction diameter with TEE</p>
<p>Abbreviation: TEE=transesophageal echocardiography.</p>
</caption>
<graphic xlink:href="10.1177_1089253211434966-fig6.tif"/></fig>
<table-wrap id="table3-1089253211434966" position="float">
<label>Table 3.</label>
<caption>
<p>Transesophageal Echocardiography Views for TAVI</p>
</caption>
<graphic alternate-form-of="table3-1089253211434966" xlink:href="10.1177_1089253211434966-table3.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">Standard TEE View</th>
<th align="center">Baseline Exam</th>
<th align="center">Intra-TAVI and Post-TAVI Exam</th>
</tr>
</thead>
<tbody>
<tr>
<td>Midesophageal aortic valve short axis</td>
<td>Morphology and calcification of leaflets</td>
<td>Valve position; coronary arteries; aortic regurgitant jets</td>
</tr>
<tr>
<td>Midesophageal aortic valve long axis</td>
<td>Diameter of LVOT, aortic annulus, and aortic root; calcification of ascending aorta</td>
<td>Position of wire and balloon for angioplasty; position of valve after deployment; aortic regurgitant jets</td>
</tr>
<tr>
<td>Transgastric long axis or deep transgastric long axis</td>
<td>Pressure gradients, blood flow velocity across native aortic valve</td>
<td>Pressure gradients across implanted aortic valve; aortic regurgitant jets</td>
</tr>
<tr>
<td>Transgastric mid–short axis</td>
<td>LV function; regional wall motion</td>
<td>LV function; regional wall motion</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-1089253211434966">
<p>Abbreviations: TAVI, transcatheter aortic valve implantation; TEE, transesophageal echocardiography; LVOT, left ventricular outflow tract; LV, left ventricle.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<fig id="fig7-1089253211434966" position="float">
<label>Figure 7.</label>
<caption>
<p>TEE midesophageal aortic valve long-axis view with balloon apparatus placed across aortic valve</p>
<p>Abbreviation: TEE=transesophageal echocardiography.</p>
</caption>
<graphic xlink:href="10.1177_1089253211434966-fig7.tif"/></fig>
<fig id="fig8-1089253211434966" position="float">
<label>Figure 8.</label>
<caption>
<p>TEE midesophageal aortic valve long-axis view demonstrating stented aortic valve prosthesis in place</p>
<p>Abbreviation: TEE=transesophageal echocardiography.</p>
</caption>
<graphic xlink:href="10.1177_1089253211434966-fig8.tif"/></fig>
<fig id="fig9-1089253211434966" position="float">
<label>Figure 9.</label>
<caption>
<p>TEE midesophageal aortic valve long-axis view with color flow Doppler illustrating small paravalvular aortic regurgitation jet after deployment of stented aortic valve prosthesis</p>
<p>Abbreviation: TEE=transesophageal echocardiography.</p>
</caption>
<graphic xlink:href="10.1177_1089253211434966-fig9.tif"/></fig>
</sec>
</sec>
<sec id="section9-1089253211434966">
<title>Pathophysiology and Postoperative Management</title>
<sec id="section10-1089253211434966">
<title>Pathophysiology: Clinical Implications</title>
<p>Replacement of the aortic valve, whether it is performed surgically while on CPB or via TAVI, usually improves the hemodynamics of the patient immediately postrelief of the mechanical obstruction. LV ejection and stroke volume will increase, albeit to a lesser degree, even in those patients with preexisting poor LV dysfunction because of the reduction in wall tension and stroke work.<sup><xref ref-type="bibr" rid="bibr31-1089253211434966">31</xref></sup> However, because of long-standing high wall stress and subsequent remodeling, there is considerably impaired diastolic function in patients with severe AS that does not recover immediately postoperatively. Following the correction of LV outflow obstruction by AVR, a regression of the LV mass begins after surgery and appears to continue for up to 10 years in some cases.<sup><xref ref-type="bibr" rid="bibr32-1089253211434966">32</xref>,<xref ref-type="bibr" rid="bibr33-1089253211434966">33</xref></sup> The decrease in muscle mass is paralleled by an improvement in both systolic and active diastolic mechanics—that is, a reduction in the time constant of the isovolumic relaxation phase of the cardiac cycle. Yet early after AVR, LV diastolic function may actually worsen, with measurable increases in diastolic stiffness that parallels an increase in interstitial collagen deposition as muscle fibers regress.<sup><xref ref-type="bibr" rid="bibr34-1089253211434966">34</xref>-<xref ref-type="bibr" rid="bibr36-1089253211434966">36</xref></sup> Reversal of diastolic stiffness and relaxation occurs late as the interstitial fibrosis slowly regresses.<sup><xref ref-type="bibr" rid="bibr35-1089253211434966">35</xref></sup></p>
</sec>
<sec id="section11-1089253211434966">
<title>Hemodynamic Management</title>
<p>Failure to recover an acceptable hemodynamic state post-TAVI must be evaluated and careful consideration given to patient management with volume resuscitation and vasoactive drugs. Preoperative LV dysfunction is a major predictor of the risk of postoperative LV dysfunction. Perioperative mortality in AVR using either open surgical AVR or TAVI, appears to be particularly elevated in patients with low preoperative valve gradients (&lt;30 mm Hg) because low gradients may result from severe LV dysfunction.<sup><xref ref-type="bibr" rid="bibr37-1089253211434966">37</xref></sup> A requirement for continued inotropic support should be anticipated in this subgroup in the immediate postoperative period.</p>
<p>Cardiac output and blood pressure are critically dependent on adequate preload and the maintenance of sinus rhythm whenever possible. It is not uncommon to have to resort to vasodilators in the immediate postoperative period to manage hypertension or elevated systemic vascular resistance. In general, unless systemic blood pressure is unacceptably elevated (usually a choice is made to keep the systolic blood pressure less than 110 mm Hg for the first 24 hours to 48 hours), careful volume resuscitation with crystalloid or colloid fluids is sufficient to reduce baroreceptor reflex–induced increases in afterload and maintain preload. It is helpful to follow interventions with frequent measurements of cardiac indices (cardiac index and systemic vascular resistance index) to generate a mini–Frank-Starling curve to assess adequacy. Periodically measuring serum lactic acid and mixed venous oxygen saturations will help confirm adequacy of systemic perfusion that can never be adequately assessed by blood pressure measurements alone. Vasodilators and inotropic agents of choice for patients undergoing TAVI are reviewed in <xref ref-type="table" rid="table4-1089253211434966">Table 4</xref>.</p>
<table-wrap id="table4-1089253211434966" position="float">
<label>Table 4.</label>
<caption>
<p>Vasodilators and Inotropes Commonly Used in TAVI</p>
</caption>
<graphic alternate-form-of="table4-1089253211434966" xlink:href="10.1177_1089253211434966-table4.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">Drugs</th>
<th align="center">Mechanism of Action</th>
<th align="center">Advantages and Attributes</th>
<th align="center">Adverse Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="4">Vasodilators</td>
</tr>
<tr>
<td>Sodium nitroprusside</td>
<td>Activations of guanylyl cyclase via release of nitric oxide or direct stimulation of enzyme<sup><xref ref-type="bibr" rid="bibr38-1089253211434966">38</xref></sup></td>
<td>Half life of 3 to 4 minutes; easily titratable</td>
<td>Reduces preload and afterload, use caution in noncompliant LV<sup><xref ref-type="bibr" rid="bibr39-1089253211434966">39</xref></sup>; cyanide toxicity; limit use to 24 hours of infusion<sup><xref ref-type="bibr" rid="bibr40-1089253211434966">40</xref>,<xref ref-type="bibr" rid="bibr41-1089253211434966">41</xref></sup></td>
</tr>
<tr>
<td>Nicardipine</td>
<td>Dihydropyridine; second-generation calcium channel blocker; inhibits L-type calcium channel in vascular smooth muscle</td>
<td>Potent vasodilation of coronary and cerebral vasculature; metabolized in liver, half life of 30 minutes; effect prolonged to 4 to 6 hours after infusion</td>
<td>Negative inotropic and dromotropic effects resulting from the effects of L-type channels on contractility and electrical conduction; use caution in patients with post-TAVI conduction defects</td>
</tr>
<tr>
<td>Clevidipine</td>
<td>Dihydropyridine; third-generation calcium channel blocker; more selective for vascular calcium channels than nicardipine</td>
<td>Potent vasodilation of coronary and cerebral vasculature; rapidly metabolized by tissue and plasma esterases; half life of 2 minutes; less effect on cardiac filling pressures<sup><xref ref-type="bibr" rid="bibr42-1089253211434966">42</xref></sup></td>
<td>Because of the short half life, it must be given by infusion</td>
</tr>
<tr>
<td colspan="4">Inotropes</td>
</tr>
<tr>
<td>Milrinone</td>
<td>Phosphodiesterase III inhibitor</td>
<td>Positive inotropic and lusitropic effect<sup><xref ref-type="bibr" rid="bibr43-1089253211434966">43</xref></sup>; vasodilation; half life of 2.5 hours</td>
<td>Not easily titrated, may need loading dose; significant hypotension is a major risk; arrhythmogenic; may inhibit platelet aggregation<sup><xref ref-type="bibr" rid="bibr44-1089253211434966">44</xref>,<xref ref-type="bibr" rid="bibr45-1089253211434966">45</xref>,<xref ref-type="bibr" rid="bibr46-1089253211434966">46</xref></sup></td>
</tr>
<tr>
<td>Epinephrine</td>
<td>α and β adrenergic agonist</td>
<td>Positive inotropic, chronotropic, and dromotropic effects, may help post-TAVI with incomplete conduction defects</td>
<td>Arrhythmogenic; increased atrial fibrillation; hyperglycemia</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn4-1089253211434966">
<p>Abbreviation: TAVI, transcatheter aortic valve implantation.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section12-1089253211434966">
<title>Postoperative Pain Management</title>
<p>Postoperative pain management is tailored to the procedural approach because the degree of invasiveness and tissue destruction can differ between the transfemoral and transapical approaches. For the transfemoral approach, heavy infiltration of the entry sites with a long-acting local anesthetic at the conclusion of the operation should be adequate. Parenteral analgesics can be added as required for any breakthrough pain. This approach can be used even if a large cut down is performed to gain vascular access. After recovery from general anesthesia and successfully tolerating oral liquids, the patient can be switched to oral analgesics. A combination of acetaminophen (1 g) and tramadol (100 mg) intravenously every 6 hours has been used with success.<sup><xref ref-type="bibr" rid="bibr47-1089253211434966">47</xref></sup></p>
<p>Pain management for the transapical approach may need to be different. The surgical approach is generally via a mini–left anterolateral thoracotomy, typically in the sixth intercostal space. Good pain management is essential to facilitate successful extubation, promote comfortable deep breathing, and allow a vigorous cough to clear secretions. By postoperative day 1, it is important to get the patient mobilized and out of bed to a chair if hemodynamically stable. Because there is always the possibility of resorting to CPB with full heparinization during these cases, it is the practice at our institution not to place epidural or paravertebral catheters preoperatively. A number of techniques can be used to provide analgesia until such a time when more commonly used acute pain management methods for postthoracotomy pain can be tried.<sup><xref ref-type="bibr" rid="bibr48-1089253211434966">48</xref>,<xref ref-type="bibr" rid="bibr49-1089253211434966">49</xref></sup></p>
<p>Various pain management strategies can be implemented for the transapical TAVI patient, including regional and neuraxial techniques (<xref ref-type="table" rid="table5-1089253211434966">Table 5</xref>). At the conclusion of surgery, the surgeons can perform intercostal nerve blocks under direct vision through the minithoracotomy. Properly performed intercostal nerve blocks with a long-acting local anesthetic can provide good pain relief for at least 12 hours. Breakthrough pain can be treated with parenteral narcotics, or these blocks can be repeated as the analgesia recedes. The gold standard for postthoracotomy pain management is considered to be a continuous infusion of local anesthetic and/or narcotic via a thoracic epidural catheter.<sup><xref ref-type="bibr" rid="bibr48-1089253211434966">48</xref></sup> There are drawbacks for epidural use in this patient population though. First, although the incidence of epidural hematoma is considered to be quite low (1:150 000 catheters),<sup><xref ref-type="bibr" rid="bibr48-1089253211434966">48</xref></sup> this assumes a normal coagulation state and functioning platelets. Some degree of heparinization during the TAVI case often results in prolonged delay of thoracic-level epidural placement until coagulation studies and platelet counts can be corrected postoperatively. If the patient was on warfarin preoperatively for chronic atrial fibrillation, bridging heparin infusions will need to be initiated and warfarin resumed. This makes the timing of epidural catheter removal an important issue. Second, hypotension can be a problem, which is related to bilateral direct blockade of the sympathetic chain from T1 to T5 and suppression of sympathetic innervation to the adrenal medulla from T6 to L1.<sup><xref ref-type="bibr" rid="bibr50-1089253211434966">50</xref></sup></p>
<table-wrap id="table5-1089253211434966" position="float">
<label>Table 5.</label>
<caption>
<p>Comparison of Pain Management Techniques for Transapical TAVI</p>
</caption>
<graphic alternate-form-of="table5-1089253211434966" xlink:href="10.1177_1089253211434966-table5.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">Pain Management Technique</th>
<th align="center">Advantages</th>
<th align="center">Disadvantages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intercostal nerve block</td>
<td>Easily performed under direct vision by surgeon at end of procedure; can achieve 12 hours of pain control with long-acting local anesthetic</td>
<td>May need to be repeated postoperatively if block recedes; need another method of pain control for breakthrough pain</td>
</tr>
<tr>
<td>Thoracic epidural analgesia</td>
<td>Gold standard for pain control<sup><xref ref-type="bibr" rid="bibr48-1089253211434966">48</xref></sup></td>
<td>Concern for epidural hematoma<sup><xref ref-type="bibr" rid="bibr48-1089253211434966">48</xref></sup>; placement may be delayed if done postoperatively because of residual heparinization; epidural catheter removal may be an issue with possibility of reinstituting warfarin therapy; hypotension caused by sympathetic blockade<sup><xref ref-type="bibr" rid="bibr50-1089253211434966">50</xref></sup></td>
</tr>
<tr>
<td>Paravertebral nerve block/catheter</td>
<td>Equally efficacious for pain control in postthoracotomy pain<sup><xref ref-type="bibr" rid="bibr49-1089253211434966">49</xref>,<xref ref-type="bibr" rid="bibr51-1089253211434966">51</xref>,<xref ref-type="bibr" rid="bibr52-1089253211434966">52</xref></sup>; less respiratory depression, nausea, vomiting, pruritus, and hypotension as compared with epidural with local anesthetic and narcotic infusion</td>
<td>Risk of pneumothorax</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn5-1089253211434966">
<p>Abbreviation: TAVI, transcatheter aortic valve implantation.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>A number of studies, including some meta-analyses, have shown the paravertebral nerve block with a continuous infusion of local anesthetic to be equally efficacious in treating postthoracotomy pain in the lung surgery patient.<sup><xref ref-type="bibr" rid="bibr49-1089253211434966">49</xref>,<xref ref-type="bibr" rid="bibr51-1089253211434966">51</xref>,<xref ref-type="bibr" rid="bibr52-1089253211434966">52</xref></sup> Comparisons between thoracic epidural and paravertebral nerve block have demonstrated no difference in pain scores, and the latter produces less respiratory depression, less nausea and vomiting, and no pruritus if epidural narcotics are used. In addition, there is less likelihood of severe hypotension with a paravertebral nerve block because the sympathetic chain is affected only unilaterally. Better hemodynamic stability translates into less need for volume resuscitation or vasopressor use just to compensate for the pain management technique.<sup><xref ref-type="bibr" rid="bibr53-1089253211434966">53</xref></sup> There are a number of excellent references available to describe the technique of inserting a paravertebral catheter under either nerve stimulator or ultrasound guidance.<sup><xref ref-type="bibr" rid="bibr54-1089253211434966">54</xref>-<xref ref-type="bibr" rid="bibr56-1089253211434966">56</xref></sup> The only unique complication for a paravertebral block as compared with a thoracic epidural is the risk of a pneumothorax. However, these patients will already have a thoracostomy tube on suction on the side to be instrumented, so there is little danger of a tension pneumothorax. A properly functioning paravertebral nerve block catheter with local anesthetic infusion produces satisfactory analgesia and allows increased mobility of the patient and rigorous pulmonary toilet.</p>
</sec>
<sec id="section13-1089253211434966">
<title>Outcomes Following TAVI</title>
<p>To date, the TAVI approach to repairing valve disorders has met with considerable success and promises to be a heavily used technology in the future. Early reports from Europe indicated that the procedure can be performed with success comparable with the open surgical approach in patients who might otherwise be deemed inoperable.<sup><xref ref-type="bibr" rid="bibr57-1089253211434966">57</xref>-<xref ref-type="bibr" rid="bibr59-1089253211434966">59</xref></sup> However, the early reports also revealed that a learning curve is involved, and new-generation and improved bioprosthetic devices have made an impact on procedural success.<sup><xref ref-type="bibr" rid="bibr58-1089253211434966">58</xref>,<xref ref-type="bibr" rid="bibr60-1089253211434966">60</xref></sup> The multicenter, multinational, randomized study of 358 severe AS patients, the PARTNER trial in the United States and Europe, has shown that overall mortality after TAVI was less than that associated with balloon valvuloplasty with standard medical therapy—30.7% versus 50.7% (hazard ratio with TAVI = 0.55; 95% confidence interval = 0.40-0.74).<sup><xref ref-type="bibr" rid="bibr61-1089253211434966">61</xref></sup></p>
<p>Reports from a number of institutions have illustrated the variability in overall procedural success and 30-day to 1- or 2-year survival (<xref ref-type="table" rid="table6-1089253211434966">Table 6</xref>). Several have examined the device itself, either the Medtronic CoreValve or the Edwards SAPIEN bioprosthesis, and found comparable survival using either model (30-day survival 88% Edwards vs 89% Medtronic).<sup><xref ref-type="bibr" rid="bibr62-1089253211434966">62</xref>,<xref ref-type="bibr" rid="bibr63-1089253211434966">63</xref></sup> The approach, transfemoral or transapical, might have more of an impact on outcome than the device design itself. A report analyzing the Belgian TAVI Registry found a discrepancy in the 1-year survival between the transfemoral approach with either the Edwards (82%) or Medtronic (78%) and the transapical one with the Edwards valve (63%).<sup><xref ref-type="bibr" rid="bibr62-1089253211434966">62</xref></sup> Unfortunately the study did not describe their decision algorithm, if any, for choosing the transfemoral versus the transapical approach. However, a recent single-center study of 107 consecutive patients undergoing either transfemoral or transapical TAVI with a balloon-expandable valve showed no significant differences in the improvement in hemodynamic, valve, or ventricular function as assessed by echocardiography or in survival at 30 days, 6 months, or 1 year.<sup><xref ref-type="bibr" rid="bibr23-1089253211434966">23</xref></sup> The study did admit to a greater likelihood of vascular injuries with the transfemoral approach.</p>
<table-wrap id="table6-1089253211434966" position="float">
<label>Table 6.</label>
<caption>
<p>Procedural Success and Mortality Post-TAVI</p>
</caption>
<graphic alternate-form-of="table6-1089253211434966" xlink:href="10.1177_1089253211434966-table6.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th/>
<th/>
<th align="center" colspan="2">Overall Mortality</th>
</tr>
<tr>
<th align="left">Study</th>
<th align="center">n</th>
<th align="center">Procedural Success</th>
<th align="center">30 Day</th>
<th align="center">1 Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grube et al<sup><xref ref-type="bibr" rid="bibr58-1089253211434966">58</xref></sup></td>
<td>86</td>
<td>88%</td>
<td>6%</td>
<td/>
</tr>
<tr>
<td>Leon et al<sup><xref ref-type="bibr" rid="bibr19-1089253211434966">19</xref></sup></td>
<td>358</td>
<td/>
<td/>
<td>30.7%</td>
</tr>
<tr>
<td>Thomas et al<sup><xref ref-type="bibr" rid="bibr63-1089253211434966">63</xref></sup></td>
<td>1038</td>
<td>95%</td>
<td>8.5%</td>
<td/>
</tr>
<tr>
<td>Buellesfeld et al<sup><xref ref-type="bibr" rid="bibr64-1089253211434966">64</xref></sup></td>
<td>126</td>
<td>83%</td>
<td>15.2%</td>
<td>38.1% (2-year mortality)</td>
</tr>
<tr>
<td>Bosmans et al<sup><xref ref-type="bibr" rid="bibr62-1089253211434966">62</xref></sup></td>
<td>328</td>
<td>97%</td>
<td>12.6% (Edwards); 11% (Medtronic)</td>
<td>18% (Edwards); 22% (Medtronic); 37% (transapical Edwards)</td>
</tr>
<tr>
<td>Figulla et al<sup><xref ref-type="bibr" rid="bibr65-1089253211434966">65</xref></sup></td>
<td>1049 (meta-analysis)</td>
<td>93.3%</td>
<td>11.4% (5.2%-23%)</td>
<td>25% (13%-35.9%)</td>
</tr>
<tr>
<td>Smith et al<sup><xref ref-type="bibr" rid="bibr20-1089253211434966">20</xref></sup></td>
<td>308</td>
<td/>
<td>3.4%</td>
<td>24.2%</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn6-1089253211434966">
<p>Abbreviation: TAVI, transcatheter aortic valve implantation.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>In nearly all cases, there is significant immediate improvement in hemodynamics after TAVI. Many additional measures of cardiac improvement, including any preexisting mitral regurgitation, are sustained at least to 1 year.<sup><xref ref-type="bibr" rid="bibr66-1089253211434966">66</xref></sup> Yet residual aortic regurgitation (AR) is common and often improves far less than mitral regurgitation and seems to be dependent on the character of the regurgitant jet.<sup><xref ref-type="bibr" rid="bibr66-1089253211434966">66</xref></sup> Mild central residual aortic jets are thought to be the consequence of aortic dilation produced by any significant paravalvular regurgitation that remains. Nonetheless, measures of the patient’s quality of life, exercise capacity, and biochemical markers of heart failure were improved and sustained.<sup><xref ref-type="bibr" rid="bibr66-1089253211434966">66</xref></sup></p>
<p>One of the largest studies to date reviewing 30-day outcomes for patients receiving Edwards-SAPIEN transcatheter valves covers 1038 patients at 32 European centers.<sup><xref ref-type="bibr" rid="bibr63-1089253211434966">63</xref></sup> Approximately half of these patients underwent a transapical TAVI, whereas the other half underwent transfemoral TAVI. Patients with transapical procedures had statistically higher logistic EuroSCOREs (25.7% vs 29.1%). Overall procedural success was found to be 93.8%. The rate of pooled vascular complications (including access site complications, aortic dissection, and other complications) was approximately 20% in the transfemoral group and less than 5% in the transapical group. Rates of valve embolization (0.3%), stroke (2.5%), permanent pacemaker implantation (7%), and coronary obstruction (0.6%) were found to be similar in both groups and when compared with other published series.</p>
<p>TAVI is not without risk. Vascular injuries occasionally requiring extensive repair, myocardial infarction, embolic stroke, renal failure, cardiac conduction disorders, valve misalignment, embolization or incomplete deployment, and hemorrhage are potential complications.<sup><xref ref-type="bibr" rid="bibr20-1089253211434966">20</xref>,<xref ref-type="bibr" rid="bibr63-1089253211434966">63</xref></sup></p>
</sec>
</sec>
<sec id="section14-1089253211434966">
<title>Specific Complications</title>
<sec id="section15-1089253211434966">
<title>Aortic Regurgitation</title>
<p>Residual AR is common after TAVI. Mild central residual AR jets are thought to be the consequence of aortic dilation produced by any significant paravalvular regurgitation that remains after placement of the stented valve apparatus.<sup><xref ref-type="bibr" rid="bibr66-1089253211434966">66</xref></sup> If the AR is central in location and mild, patients seem to tolerate this without difficulty. If central AR is moderate or severe, replacement of the valve, by using a valve-in-valve procedure in which another stented valve is deployed within the first prosthesis, may need to be done.<sup><xref ref-type="bibr" rid="bibr67-1089253211434966">67</xref></sup></p>
<p>Because of the sutureless nature of the transcatheter valve, it must be larger than the aortic annulus to minimize the amount of paravalvular AR and for the implant to seat properly. To use the Edwards SAPIEN system, the native valve annulus must be larger than 18 mm but not larger than 24 mm.<sup><xref ref-type="bibr" rid="bibr27-1089253211434966">27</xref></sup> As the transcatheter valve systems are perfected and technologically developed, patients with smaller and larger annular sizes may be able to undergo TAVI. In cases where there is significant paravalvular AR, the stent and valve apparatus may be reballooned to try to improve the attachment and decrease paravalvular regurgitation.<sup><xref ref-type="bibr" rid="bibr21-1089253211434966">21</xref></sup></p>
<p>In a recent investigation of 50 patients who underwent CoreValve TAVI, Sherif and colleagues<sup><xref ref-type="bibr" rid="bibr68-1089253211434966">68</xref></sup> developed a model to predict the development of AR based on an increased angle between the LVOT and the ascending aorta as well as the depth of implantation into the LVOT. On both univariate and multivariate analysis, as the angle between the LVOT and ascending aorta increased, the chance of developing significant AR increased, and if the depth of the prosthesis was less than 10 mm from the noncoronary cusp to the proximal end of the stent frame (deepest portion of the LV), AR was minimal.<sup><xref ref-type="bibr" rid="bibr68-1089253211434966">68</xref></sup> Rajani and colleagues<sup><xref ref-type="bibr" rid="bibr69-1089253211434966">69</xref></sup> evaluated AR in patients who underwent TAVI in the immediate postoperative period and then again at 1 year postprocedure to assess if the AR decreases with time. It was found that 86% of patients undergoing TAVI had immediate postprocedure AR, and at 1 year, 77% of patients continued to have trace to mild AR.<sup><xref ref-type="bibr" rid="bibr69-1089253211434966">69</xref></sup></p>
</sec>
<sec id="section16-1089253211434966">
<title>Malposition of the Valve</title>
<p>Once the stent has been expanded with the prosthetic valve in place, it is quite difficult to manipulate or adjust the position within the LVOT or aortic annulus. Malposition can lead to embolization of the stent and valve apparatus, obstruction of the ostia of the coronary arteries, paravalvular regurgitation, impedance of the mitral valve leaflets, and arrhythmias.<sup><xref ref-type="bibr" rid="bibr70-1089253211434966">70</xref></sup> In a retrospective review of 300 patients, Tay and colleagues<sup><xref ref-type="bibr" rid="bibr71-1089253211434966">71</xref></sup> found 7 instances of valve embolization, all of which immediately followed valve deployment. Although the embolized valves were left in place in these patients, other instances of valve embolization require removal. This is generally accomplished via open surgical approach while on CPB; however, there is a report of valve removal through the existing transapical access.<sup><xref ref-type="bibr" rid="bibr72-1089253211434966">72</xref></sup> A case report of a transapical TAVI that was originally implanted too low in the LV outflow tract allowed the patient to have a reduction in symptoms for approximately 6 months.<sup><xref ref-type="bibr" rid="bibr70-1089253211434966">70</xref></sup> The authors theorize that the patient had relief of severe AS and heart failure symptoms during those first 6 months because of the balloon valvuloplasty of the original native aortic valve. Once the native aortic valve restenosed, the patient again became symptomatic. This case required a second transapical TAVI in a “higher” position than the first, but the first TAVI was found to be functioning normally.</p>
</sec>
<sec id="section17-1089253211434966">
<title>Neurological Complications</title>
<p>Balloon valvuloplasty and deployment of the bioprosthetic aortic valve in heavily calcified native valves or the aortic root can result in showering of debris resulting in cerebral embolic stroke. The incidence of clinical stroke has been reported to range from 2.5% to 10%.<sup><xref ref-type="bibr" rid="bibr20-1089253211434966">20</xref>,<xref ref-type="bibr" rid="bibr58-1089253211434966">58</xref>,<xref ref-type="bibr" rid="bibr61-1089253211434966">61</xref>,<xref ref-type="bibr" rid="bibr63-1089253211434966">63</xref></sup> The actual incidence may be even higher. In a study of 32 patients undergoing transfemoral TAVI with either the Edwards or Medtronic device, evidence for periprocedural cerebral ischemia, both apparent and clinically silent, was sought using serial diffusion-weighted magnetic resonance imaging (MRI) between 2.5 to 4.5 days postprocedure and then again at 3 months.<sup><xref ref-type="bibr" rid="bibr73-1089253211434966">73</xref></sup> They found new foci of restricted diffusion on cerebral MRI in 27 of 32 patients (84%, <italic>P</italic> = .011) when compared with patients (historical controls) who underwent surgical AVR (10 of 21 patients; 48%). More recently, a prospective multicenter study included 60 patients who underwent cerebral diffusion-weighted MRI the day before and within 6 days following their TAVI procedure (transfemoral, 29; transapical, 31).<sup><xref ref-type="bibr" rid="bibr74-1089253211434966">74</xref></sup> Baseline MRI showed no acute lesions, but 32 patients (53%) had old lesions; 41 patients (68%) had 251 new cerebral ischemic lesions at 4 days postprocedure (transfemoral, 66%; transapical, 71%). Only 2 patients (3.3%) had clinical signs of stroke. No significant difference was noted in the rate of stroke when comparing transfemoral and transapical approaches. Arnold et al<sup><xref ref-type="bibr" rid="bibr75-1089253211434966">75</xref></sup> performed cerebral MRIs on 25 patients both before and after transapical valve replacement. It was found that 17 patients (68%) had new cerebral lesions 6 days postprocedure, but only 5 patients showed clinical signs of stroke. Only 1 patient in this series had permanent clinical changes. The clinical implication of these findings for postoperative management is to follow a neurological exam closely for the first few days and maintain mean arterial pressure adequate for cerebral perfusion. Findings of significant new stroke may warrant adjusting the timing of any required anticoagulation to avoid hemorrhagic conversion.</p>
</sec>
<sec id="section18-1089253211434966">
<title>Cardiac Conduction Disorders</title>
<p>Arrhythmias are a common source of morbidity during TAVI. It is estimated that significant atrioventricular (AV) nodal block occurs 5 times more frequently in the TAVI than in the surgical AVR population to the extent that a permanent pacemaker is required.<sup><xref ref-type="bibr" rid="bibr76-1089253211434966">76</xref></sup> Several reports currently estimate that 33% to 65% of all patients undergoing TAVI are experiencing sufficient conduction block to require a permanent pacemaker placement.<sup><xref ref-type="bibr" rid="bibr76-1089253211434966">76</xref>-<xref ref-type="bibr" rid="bibr80-1089253211434966">80</xref></sup></p>
<p>New onset complete AV block, Mobitz Type 2, or left bundle branch block (LBBB) are the most commonly reported findings. The cause is likely compression and injury of the LV outlet and/or wall around the valve annulus by the valve deployment system. The injury manifests usually within the first 24 hours and shows little evidence of recovery that is sufficient enough to avoid a pacemaker. However, reexamination at up to a year postprocedure has indicated that some recovery does occur.<sup><xref ref-type="bibr" rid="bibr79-1089253211434966">79</xref></sup> In a small study evaluating the effect of new conduction abnormalities on LV function, patients who sustained new conduction delays showed no improvement in ejection fraction as compared with patients without new conduction delays.<sup><xref ref-type="bibr" rid="bibr80-1089253211434966">80</xref></sup> Although there may be a trend to produce more LBBB by deployment of the self-expanding Medtronic CoreValve than the Edwards balloon-expandable SAPIEN valve, it is not clear.<sup><xref ref-type="bibr" rid="bibr78-1089253211434966">78</xref></sup> Several studies have concluded that the best independent predictor of the need for postoperative permanent pacemaker support is a preexisting conduction defect, especially RBBB.<sup><xref ref-type="bibr" rid="bibr76-1089253211434966">76</xref>,<xref ref-type="bibr" rid="bibr78-1089253211434966">78</xref>,<xref ref-type="bibr" rid="bibr79-1089253211434966">79</xref>,<xref ref-type="bibr" rid="bibr81-1089253211434966">81</xref></sup> The portion of the conduction system most at risk during aortic valve prosthesis deployment is the LBBB, establishing the likelihood of complete interruption of the cardiac impulse. Postoperative partial conduction disorders will greatly influence selection of antihypertensive medications. Accordingly, it is best to avoid any drugs known to interfere with the AV node or Purkinje system such as β-blockers, calcium channel blockers, digoxin, or even amiodarone unless a reliable pacemaker is in place.</p>
</sec>
<sec id="section19-1089253211434966">
<title>Acute Kidney Injury</title>
<p>Surgical replacement of the aortic valve with CPB has been established as a relatively safe procedure in those without extensive comorbidities.<sup><xref ref-type="bibr" rid="bibr82-1089253211434966">82</xref></sup> However, the incidence of acute kidney injury (AKI) following cardiac surgery is in the range of 4% to 30%.<sup><xref ref-type="bibr" rid="bibr83-1089253211434966">83</xref>,<xref ref-type="bibr" rid="bibr84-1089253211434966">84</xref></sup> It is associated with substantial mortality as the severity of the AKI increases,<sup><xref ref-type="bibr" rid="bibr85-1089253211434966">85</xref>-<xref ref-type="bibr" rid="bibr87-1089253211434966">87</xref></sup> even in TAVI patients (mortality 23% in those with AKI vs in those with preserved renal function 4%, <italic>P</italic> = .011).<sup><xref ref-type="bibr" rid="bibr88-1089253211434966">88</xref></sup> In addition, it results in significant lengthening of ICU and hospital stays. The problem is no less significant in the TAVI population, even though CPB is avoided. Prospective studies of patients undergoing TAVI demonstrate that AKI can occur in 20% to 50% of patients, with about 2.5% to 20% requiring renal replacement therapy (RRT).<sup><xref ref-type="bibr" rid="bibr89-1089253211434966">89</xref>-<xref ref-type="bibr" rid="bibr91-1089253211434966">91</xref></sup> Although AKI is a risk in TAVI, especially in those with preexisting renal insufficiency, the risk is less than that in surgical AVR. After propensity score adjustment, the incidence of AKI was lower (<italic>P</italic> = .014) in the TAVI patients (9.2%, with 2.5% requiring RRT) than in surgical patients (25.9%, with 8.7% requiring RRT).<sup><xref ref-type="bibr" rid="bibr90-1089253211434966">90</xref></sup> Analysis of a multitude of potential predictive factors has been reduced to a few that reach significance. As might be expected, poor preexisting renal function with an elevated serum creatinine level (&gt;1.1 mg/dL) and estimated glomerular filtration rate &lt;60 mL/min/1.72 m<sup>2</sup> is highly predictive of AKI (odds ratio = 3.7; 95% confidence interval = 1.24-11.3).<sup><xref ref-type="bibr" rid="bibr89-1089253211434966">89</xref>,<xref ref-type="bibr" rid="bibr91-1089253211434966">91</xref></sup> Other factors identified were periprocedural blood transfusions, preexisting hypertension, peripheral vascular disease, previous MI, and postoperative leukocytosis.<sup><xref ref-type="bibr" rid="bibr88-1089253211434966">88</xref>,<xref ref-type="bibr" rid="bibr90-1089253211434966">90</xref>,<xref ref-type="bibr" rid="bibr91-1089253211434966">91</xref></sup></p>
</sec>
<sec id="section20-1089253211434966">
<title>Myocardial Infarction</title>
<p>The potential for myocardial ischemia and infarction is high during the TAVI procedure and in the postoperative period. The procedure involves many stages where myocardial damage may be produced. Significant tissue compression and bruising may be caused by stiff guidewires, the balloon, and introduction of the valve prosthesis system. During the procedure, there are several periods where extreme hypotension may result, the heart is paced at extremely high rates, and global ischemia is produced by balloon valvuloplasty and valve deployment. Focal injuries may occur if calcific deposits or other debris embolize into the coronary ostia. Detection postoperatively is often based on clinical suspicion, excessive vasoactive support requirements, ventricular arrhythmias, and using echocardiography to look for new regions of wall motion abnormality. Cardiac markers are of little value because even uncomplicated procedures produce troponin leaks. Rodes-Cabau et al<sup><xref ref-type="bibr" rid="bibr92-1089253211434966">92</xref></sup> studied the prognostic value of cardiac markers and the significance of the myocardial injury following TAVI. The rise in cardiac troponin T level peaked about 6 to 12 hours after a transfemoral TAVI as compared with around 48 hours following a transapical approach. Notable findings in their analysis included a highly significant change in cardiac troponin T and creatine kinase-myocardial band when compared with the transfemoral approach. Baseline renal insufficiency increased the recorded levels of cardiac markers but that may reflect less clearance rather than worse myocardial injury. Other significant associations with increased myocardial injury were the number of cardiac pacing runs (&gt;6) during the case and the median ratio of the valve size to aortic annulus size (&gt;1.15).<sup><xref ref-type="bibr" rid="bibr92-1089253211434966">92</xref></sup></p>
</sec>
<sec id="section21-1089253211434966">
<title>Vascular Injury</title>
<p>Vascular injury is one of the most common sources of TAVI morbidity, particularly in patients undergoing the transfemoral approach. Complications may occur at the access sites and at perivalvular sites during implantation, including acute aortic dissection.<sup><xref ref-type="bibr" rid="bibr93-1089253211434966">93</xref></sup> Vascular complication rates have been reported to be as high as 27%.<sup><xref ref-type="bibr" rid="bibr94-1089253211434966">94</xref></sup> In 130 patients undergoing transfemoral replacement, major vascular complications were found to be predictive of 30-day mortality. Risk factors noted in this study for vascular injury included high sheath size to femoral artery ratio, center experience, and femoral calcification. Damage to vessels can result in massive hemorrhage and the need for significant resuscitation and blood transfusion.</p>
</sec>
</sec>
<sec id="section22-1089253211434966" sec-type="conclusions">
<title>Conclusion</title>
<p>Senile calcific AS is a common indication for AVR in patients older than 65 years. Unfortunately, these patients often have significant medical comorbidities that convey increased risk for further morbidity and mortality for surgical valve replacement. TAVI, although still in its infancy, is growing into a viable option for patients at such an increased risk. As TAVI continues to be developed and perfected, it is expected that patients who are at lower perioperative risk will be able to benefit from this technology.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="conflict">
<p>The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure">
<p>The authors received no financial support for the research, authorship, and/or publication of this article.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1089253211434966">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stewart</surname><given-names>BF</given-names></name>
<name><surname>Siscovick</surname><given-names>D</given-names></name>
<name><surname>Lind</surname><given-names>BK</given-names></name><etal/>
</person-group>. <article-title>Clinical factors associated with calcific aortic valve disease: Cardiovascular Health Study</article-title>. <source>J Am Coll Cardiol</source>. <year>1997</year>;<volume>29</volume>:<fpage>630</fpage>-<lpage>634</lpage>.</citation>
</ref>
<ref id="bibr2-1089253211434966">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Otto</surname><given-names>CM</given-names></name>
<name><surname>Burwash</surname><given-names>IG</given-names></name>
<name><surname>Legget</surname><given-names>ME</given-names></name><etal/>
</person-group>. <article-title>Prospective study of asymptomatic valvular aortic stenosis: clinical, echocardiographic, and exercise predictors of outcome</article-title>. <source>Circulation</source>. <year>1997</year>;<volume>95</volume>:<fpage>2262</fpage>-<lpage>2270</lpage>.</citation>
</ref>
<ref id="bibr3-1089253211434966">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bonow</surname><given-names>RO</given-names></name>
<name><surname>Carabello</surname><given-names>B</given-names></name>
<name><surname>de Leon</surname><given-names>AC</given-names><suffix>Jr.</suffix></name>
</person-group> <article-title>Guidelines for the management of patients with valvular heart disease: executive summary</article-title>. <collab>A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients with Valvular Heart Disease)</collab>. <source>Circulation</source>. <year>1998</year>;<volume>98</volume>:<fpage>1949</fpage>-<lpage>1984</lpage>.</citation>
</ref>
<ref id="bibr4-1089253211434966">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ross</surname><given-names>J</given-names></name>
<name><surname>Braumwald</surname><given-names>E</given-names></name>
</person-group>. <article-title>Aortic stenosis</article-title>. <source>Circulation</source>. <year>1968</year>; <volume>38</volume>(<issue>suppl 5</issue>):<fpage>61</fpage>-<lpage>67</lpage>.</citation>
</ref>
<ref id="bibr5-1089253211434966">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>O’Brien</surname><given-names>KD</given-names></name>
<name><surname>Zhao</surname><given-names>XQ</given-names></name>
<name><surname>Shavelle</surname><given-names>DM</given-names></name><etal/>
</person-group>. <article-title>Hemodynamic effects of the angiotensin-converting enzyme inhibitor, ramipril, in patients with mild to moderate aortic stenosis and preserved left ventricular function</article-title>. <source>J Investig Med</source>. <year>2004</year>;<volume>52</volume>:<fpage>185</fpage>-<lpage>191</lpage>.</citation>
</ref>
<ref id="bibr6-1089253211434966">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rossebo</surname><given-names>AB</given-names></name>
<name><surname>Pedersen</surname><given-names>TR</given-names></name>
<name><surname>Boman</surname><given-names>K</given-names></name><etal/>
</person-group>. <article-title>Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis</article-title>. <source>N Engl J Med</source>. <year>2008</year>;<volume>359</volume>:<fpage>1343</fpage>-<lpage>1356</lpage>.</citation>
</ref>
<ref id="bibr7-1089253211434966">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Varadarajan</surname><given-names>P</given-names></name>
<name><surname>Kapoor</surname><given-names>N</given-names></name>
<name><surname>Ramesh</surname><given-names>C</given-names></name>
<etal/>
</person-group>. <source>Ann Thorac Surg</source>. <year>2006</year>;<volume>82</volume>:<fpage>2111</fpage>-<lpage>2115</lpage>.</citation>
</ref>
<ref id="bibr8-1089253211434966">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bonow</surname><given-names>RO</given-names></name>
<name><surname>Carabello</surname><given-names>BA</given-names></name>
<name><surname>Chatterjee</surname><given-names>K</given-names></name><etal/>
</person-group>. <article-title>American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines</article-title>. <source>J Am Coll Cardiol</source>. <year>2008</year>;<volume>52</volume>:<fpage>e1</fpage>-<lpage>e142</lpage>.</citation>
</ref>
<ref id="bibr9-1089253211434966">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bonow</surname><given-names>RO</given-names></name>
<name><surname>Carabello</surname><given-names>BA</given-names></name>
<name><surname>Chatterjee</surname><given-names>K</given-names></name><etal/>
</person-group>. <article-title>Guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines</article-title>. <source>J Am Coll Cardiol</source>. <year>2006</year>;<volume>48</volume>:<fpage>e1</fpage>-<lpage>e148</lpage>.</citation>
</ref>
<ref id="bibr10-1089253211434966">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vahanian</surname><given-names>A</given-names></name>
<name><surname>Baumgartner</surname><given-names>H</given-names></name>
<name><surname>Bax</surname><given-names>J</given-names></name><etal/>
</person-group>. <article-title>Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology</article-title>. <source>Eur Heart J</source>. <year>2007</year>;<volume>28</volume>:<fpage>230</fpage>-<lpage>268</lpage>.</citation>
</ref>
<ref id="bibr11-1089253211434966">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cribier</surname><given-names>A</given-names></name>
<name><surname>Eltchaninoff</surname><given-names>H</given-names></name>
<name><surname>Bash</surname><given-names>A</given-names></name><etal/>
</person-group>. <article-title>Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case description</article-title>. <source>Circulation</source>. <year>2002</year>;<volume>106</volume>:<fpage>3006</fpage>-<lpage>3008</lpage>.</citation>
</ref>
<ref id="bibr12-1089253211434966">
<label>12.</label>
<citation citation-type="web"><collab>European System for Cardiac Operative Risk Evaluation</collab>. <comment><ext-link ext-link-type="uri" xlink:href="http://www.euroscore.org">www.euroscore.org</ext-link></comment>. <access-date>Accessed December 28, 2011</access-date>.</citation>
</ref>
<ref id="bibr13-1089253211434966">
<label>13.</label>
<citation citation-type="web"><collab>Online STS risk calculator</collab>. <comment><ext-link ext-link-type="uri" xlink:href="http://209.220.160.181/STSWebRiskCalc261/">http://209.220.160.181/STSWebRiskCalc261/</ext-link></comment>. <access-date>Accessed December 28, 2011</access-date>.</citation>
</ref>
<ref id="bibr14-1089253211434966">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gummert</surname><given-names>JF</given-names></name>
<name><surname>Funkat</surname><given-names>A</given-names></name>
<name><surname>Osswald</surname><given-names>B</given-names></name><etal/>
</person-group>. <article-title>EuroSCORE overestimates the risk of cardiac surgery: results from the national registry of the German Society of Thoracic and Cardiovascular Surgery</article-title>. <source>Clin Res Cardiol</source>. <year>2009</year>;<volume>98</volume>:<fpage>363</fpage>-<lpage>369</lpage>.</citation>
</ref>
<ref id="bibr15-1089253211434966">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Osswald</surname><given-names>BR</given-names></name>
<name><surname>Gegouskov</surname><given-names>V</given-names></name>
<name><surname>Badowski-Zyla</surname><given-names>D</given-names></name><etal/>
</person-group>. <article-title>Overestimation of aortic valve replacement risk by EuroSCORE: implications for percutaneous valve replacement</article-title>. <source>Eur Heart J</source>. <year>2009</year>;<volume>30</volume>:<fpage>74</fpage>-<lpage>80</lpage>.</citation>
</ref>
<ref id="bibr16-1089253211434966">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wendt</surname><given-names>D</given-names></name>
<name><surname>Osswald</surname><given-names>BR</given-names></name>
<name><surname>Kayser</surname><given-names>K</given-names></name><etal/>
</person-group>. <article-title>Society of Thoracic Surgeons score is superior to the EuroSCORE determining mortality in high risk patients undergoing isolated aortic valve replacement</article-title>. <source>Ann Thorac Surg</source>. <year>2009</year>;<volume>88</volume>:<fpage>468</fpage>-<lpage>475</lpage>.</citation>
</ref>
<ref id="bibr17-1089253211434966">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dewey</surname><given-names>TM</given-names></name>
<name><surname>Brown</surname><given-names>D</given-names></name>
<name><surname>Ryan</surname><given-names>WH</given-names></name><etal/>
</person-group>. <article-title>Reliability of risk algorithms in predicting early and late operative outcomes in high-risk patients undergoing aortic valve replacement</article-title>. <source>J Thorac Cardiovasc Surg</source>. <year>2008</year>;<volume>135</volume>:<fpage>180</fpage>-<lpage>187</lpage>.</citation>
</ref>
<ref id="bibr18-1089253211434966">
<label>18.</label>
<citation citation-type="gov">
<comment><ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov">ClinicalTrials.gov</ext-link></comment>. <article-title>THE PARTNER TRIAL: Placement of AoRTic TraNscathetER Valve Trial</article-title>. <comment><ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov/ct2/show/NCT00530894">http://clinicaltrials.gov/ct2/show/NCT00530894</ext-link></comment>. <access-date>Accessed December 28, 2011</access-date>.</citation>
</ref>
<ref id="bibr19-1089253211434966">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Leon</surname><given-names>MB</given-names></name>
<name><surname>Smith</surname><given-names>CR</given-names></name>
<name><surname>Mack</surname><given-names>M</given-names></name><etal/>
</person-group>. <article-title>Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery</article-title>. <source>N Engl J Med</source>. <year>2010</year>;<volume>363</volume>:<fpage>1597</fpage>-<lpage>1607</lpage>.</citation>
</ref>
<ref id="bibr20-1089253211434966">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Smith</surname><given-names>CR</given-names></name>
<name><surname>Leon</surname><given-names>MB</given-names></name>
<name><surname>Mack</surname><given-names>MJ</given-names></name>
<etal/>
</person-group>; <collab>PARTNER Trial Investigators</collab>. <article-title>Transcatheter versus surgical aortic-valve replacement in high-risk patients</article-title>. <source>N Engl J Med</source>. <year>2011</year>;<volume>364</volume>:<fpage>2187</fpage>-<lpage>2198</lpage>.</citation>
</ref>
<ref id="bibr21-1089253211434966">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Leon</surname><given-names>MB</given-names></name>
<name><surname>Kodali</surname><given-names>S</given-names></name>
<name><surname>Williams</surname><given-names>M</given-names></name><etal/>
</person-group>. <article-title>Transcatheter aortic valve replacement in patients with critical aortic stenosis: rationale, device descriptions, early clinical experiences, and perspectives</article-title>. <source>Semin Thorac Cardiovasc Surg</source>. <year>2006</year>;<volume>18</volume>:<fpage>165</fpage>-<lpage>174</lpage>.</citation>
</ref>
<ref id="bibr22-1089253211434966">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Eltchaninoff</surname><given-names>H</given-names></name>
<name><surname>Prat</surname><given-names>A</given-names></name>
<name><surname>Gilard</surname><given-names>M</given-names></name>
<etal/>
</person-group>; <collab>FRANCE Registry Investigators</collab>. <article-title>Transcatheter aortic valve implantation: early results of the FRANCE (FRench Aortic National CoreValve and Edwards) registry</article-title>. <source>Eur Heart J</source>. <year>2011</year>;<volume>32</volume>:<fpage>191</fpage>-<lpage>197</lpage>.</citation>
</ref>
<ref id="bibr23-1089253211434966">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ewe</surname><given-names>SH</given-names></name>
<name><surname>Delgado</surname><given-names>V</given-names></name>
<name><surname>Ng</surname><given-names>AC</given-names></name><etal/>
</person-group>. <article-title>Outcomes after transcatheter aortic valve implantation: transfemoral versus transapical approach</article-title>. <source>Ann Thorac Surg</source>. <year>2011</year>;<volume>92</volume>:<fpage>1244</fpage>-<lpage>1251</lpage>.</citation>
</ref>
<ref id="bibr24-1089253211434966">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Johansson</surname><given-names>M</given-names></name>
<name><surname>Nozohoor</surname><given-names>S</given-names></name>
<name><surname>Kimblad</surname><given-names>PO</given-names></name><etal/>
</person-group>. <article-title>Transapical versus transfemoral aortic valve implantation: a comparison of survival and safety</article-title>. <source>Ann Thorac Surg</source>. <year>2011</year>;<volume>91</volume>:<fpage>57</fpage>-<lpage>63</lpage>.</citation>
</ref>
<ref id="bibr25-1089253211434966">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bleiziffer</surname><given-names>S</given-names></name>
<name><surname>Ruge</surname><given-names>H</given-names></name>
<name><surname>Mazzitelli</surname><given-names>D</given-names></name><etal/>
</person-group>. <article-title>Survival after transapical and transfemoral aortic valve implantation: talking about two different patient populations</article-title>. <source>J Thorac Cardiovasc Surg</source>. <year>2009</year>;<volume>138</volume>:<fpage>1073</fpage>-<lpage>1080</lpage>.</citation>
</ref>
<ref id="bibr26-1089253211434966">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wilson</surname><given-names>A</given-names></name>
<name><surname>Toggweiler</surname><given-names>S</given-names></name>
<name><surname>Webb</surname><given-names>JG</given-names></name>
</person-group>. <article-title>Transfemoral aortic valve replacement with the SAPIEN XT valve: step-by-step</article-title>. <source>Semin Thorac Cardiovasc Surg</source>. <year>2011</year>;<volume>23</volume>:<fpage>51</fpage>-<lpage>54</lpage>.</citation>
</ref>
<ref id="bibr27-1089253211434966">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zajarias</surname><given-names>A</given-names></name>
<name><surname>Cribier</surname><given-names>AG</given-names></name>
</person-group>. <article-title>Outcomes and safety of percutaneous aortic valve replacement</article-title>. <source>J Am Coll Cardiol</source>. <year>2009</year>;<volume>53</volume>: <fpage>1829</fpage>-<lpage>1836</lpage>.</citation>
</ref>
<ref id="bibr28-1089253211434966">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mukherjee</surname><given-names>C</given-names></name>
<name><surname>Walther</surname><given-names>T</given-names></name>
<name><surname>Borger</surname><given-names>MA</given-names></name><etal/>
</person-group>. <article-title>Awake transapical aortic valve implantation using thoracic epidural anesthesia</article-title>. <source>Ann Thorac Surg</source>. <year>2009</year>;<volume>88</volume>:<fpage>992</fpage>-<lpage>994</lpage>.</citation>
</ref>
<ref id="bibr29-1089253211434966">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vavuranakis</surname><given-names>M</given-names></name>
<name><surname>Voudris</surname><given-names>V</given-names></name>
<name><surname>Vrachatis</surname><given-names>DA</given-names></name><etal/>
</person-group>. <article-title>Transcatheter aortic valve implantation, patient selection process and procedures: two centres’ experience of the intervention without general anesthesia</article-title>. <source>Hellenic J Cardiol</source>. <year>2010</year>;<volume>51</volume>:<fpage>492</fpage>-<lpage>500</lpage>.</citation>
</ref>
<ref id="bibr30-1089253211434966">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bagur</surname><given-names>R</given-names></name>
<name><surname>Rodes-Cabau</surname><given-names>J</given-names></name>
<name><surname>Doyle</surname><given-names>D</given-names></name><etal/>
</person-group>. <article-title>Usefulness of TEE as the primary imaging technique to guide transcatheter transapical aortic valve implantation</article-title>. <source>JACC Cardiovasc Imaging</source>. <year>2011</year>;<volume>4</volume>:<fpage>115</fpage>-<lpage>124</lpage>.</citation>
</ref>
<ref id="bibr31-1089253211434966">
<label>31.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Smith</surname><given-names>N</given-names></name>
<name><surname>McAnulty</surname><given-names>JH</given-names></name>
<name><surname>Rahimtoola</surname><given-names>SH</given-names></name>
</person-group>. <article-title>Severe aortic stenosis with impaired left ventricular function and clinical heart failure: results of valve replacement</article-title>. <source>Circulation</source>. <year>1978</year>;<volume>58</volume>:<fpage>255</fpage>-<lpage>264</lpage>.</citation>
</ref>
<ref id="bibr32-1089253211434966">
<label>32.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Krayenbuehl</surname><given-names>HP</given-names></name>
<name><surname>Hess</surname><given-names>OM</given-names></name>
<name><surname>Monrad</surname><given-names>ES</given-names></name><etal/>
</person-group>. <article-title>Left ventricular myocardial structure in aortic valve disease before, intermediate, and late after aortic valve replacement</article-title>. <source>Circulation</source>. <year>1989</year>;<volume>79</volume>:<fpage>744</fpage>-<lpage>755</lpage>.</citation>
</ref>
<ref id="bibr33-1089253211434966">
<label>33.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Christakis</surname><given-names>GT</given-names></name>
<name><surname>Joyner</surname><given-names>CD</given-names></name>
<name><surname>Morgan</surname><given-names>CD</given-names></name><etal/>
</person-group>. <article-title>Left ventricular mass regression early after aortic valve replacement</article-title>. <source>Ann Thorac Surg</source>. <year>1996</year>;<volume>62</volume>:<fpage>1084</fpage>-<lpage>1089</lpage>.</citation>
</ref>
<ref id="bibr34-1089253211434966">
<label>34.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hess</surname><given-names>OM</given-names></name>
<name><surname>Ritter</surname><given-names>M</given-names></name>
<name><surname>Schneider</surname><given-names>J</given-names></name><etal/>
</person-group>. <article-title>Diastolic stiffness and myocardial structure in aortic valve disease before and after valve replacement</article-title>. <source>Circulation</source>. <year>1984</year>;<volume>69</volume>:<fpage>855</fpage>-<lpage>865</lpage>.</citation>
</ref>
<ref id="bibr35-1089253211434966">
<label>35.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Villari</surname><given-names>B</given-names></name>
<name><surname>Vassalli</surname><given-names>G</given-names></name>
<name><surname>Monrad</surname><given-names>ES</given-names></name><etal/>
</person-group>. <article-title>Normalization of diastolic dysfunction in aortic stenosis late after valve replacement</article-title>. <source>Circulation</source>. <year>1995</year>;<volume>91</volume>:<fpage>2353</fpage>-<lpage>2358</lpage>.</citation>
</ref>
<ref id="bibr36-1089253211434966">
<label>36.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Villari</surname><given-names>B</given-names></name>
<name><surname>Sossalla</surname><given-names>S</given-names></name>
<name><surname>Ciampi</surname><given-names>Q</given-names></name><etal/>
</person-group>. <article-title>Persistent diastolic dysfunction late after valve replacement in severe aortic regurgitation</article-title>. <source>Circulation</source>. <year>2009</year>;<volume>120</volume>:<fpage>2386</fpage>-<lpage>2392</lpage>.</citation>
</ref>
<ref id="bibr37-1089253211434966">
<label>37.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Blitz</surname><given-names>LR</given-names></name>
<name><surname>Gorman</surname><given-names>M</given-names></name>
<name><surname>Herrmann</surname><given-names>HC</given-names></name>
</person-group>. <article-title>Results of aortic valve replacement for aortic stenosis with relatively low transvalvular pressure gradients</article-title>. <source>Am J Cardiol</source>. <year>1998</year>;<volume>81</volume>: <fpage>358</fpage>-<lpage>362</lpage>.</citation>
</ref>
<ref id="bibr38-1089253211434966">
<label>38.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tsai</surname><given-names>S-C</given-names></name>
<name><surname>Adamik</surname><given-names>R</given-names></name>
<name><surname>Manganiello</surname><given-names>VC</given-names></name>
<name><surname>Moss</surname><given-names>J</given-names></name>
</person-group>. <article-title>Effects of nitroprusside and nitroglycerin on cGMP content and PGI<sub>2</sub> formation in aorta and vena cava</article-title>. <source>Biochem Pharmacol</source>. <year>1989</year>;<volume>38</volume>:<fpage>61</fpage>-<lpage>65</lpage>.</citation>
</ref>
<ref id="bibr39-1089253211434966">
<label>39.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cohen</surname><given-names>JN</given-names></name>
<name><surname>Franciosa</surname><given-names>JA</given-names></name>
<name><surname>Francis</surname><given-names>GS</given-names></name><etal/>
</person-group>. <article-title>Effect of short-term infusion of sodium nitroprusside on mortality rate in acute myocardial infarction complicated by left ventricular failure</article-title>. <source>N Engl J Med</source>. <year>1982</year>;<volume>306</volume>:<fpage>1129</fpage>-<lpage>1135</lpage>.</citation>
</ref>
<ref id="bibr40-1089253211434966">
<label>40.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Friederich</surname><given-names>JA</given-names></name>
<name><surname>Butterworth</surname><given-names>JF</given-names></name>
</person-group>. <article-title>Sodium nitroprusside: twenty years and counting</article-title>. <source>Anesth Analg</source>. <year>1995</year>;<volume>81</volume>:<fpage>152</fpage>-<lpage>162</lpage>.</citation>
</ref>
<ref id="bibr41-1089253211434966">
<label>41.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dupuis</surname><given-names>J</given-names></name>
<name><surname>LaLonde</surname><given-names>G</given-names></name>
<name><surname>Lemieux</surname><given-names>R</given-names></name>
<name><surname>Rouleau</surname><given-names>JL</given-names></name>
</person-group>. <article-title>Tolerance to intravenous nitroglycerin in patients with congestive heart failure: role of increased intravascular volume, neurohumoral activation, and lack of prevention with <italic>N</italic>-acetylcysteine</article-title>. <source>J Am Coll Cardiol</source>. <year>1990</year>;<volume>16</volume>:<fpage>923</fpage>-<lpage>931</lpage>.</citation>
</ref>
<ref id="bibr42-1089253211434966">
<label>42.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Levy</surname><given-names>JH</given-names></name>
<name><surname>Mancao</surname><given-names>MY</given-names></name>
<name><surname>Gitter</surname><given-names>R</given-names></name><etal/>
</person-group>. <article-title>Clevidipine effectively and rapidly controls blood pressure preoperatively in cardiac surgery patients: the results of the randomized, placebo-controlled efficacy study of clevidipine assessing its preoperative antihypertensive effect in cardiac surgery-1</article-title>. <source>Anesth Analg</source>. <year>2007</year>;<volume>105</volume>:<fpage>918</fpage>-<lpage>925</lpage>.</citation>
</ref>
<ref id="bibr43-1089253211434966">
<label>43.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jaski</surname><given-names>BE</given-names></name>
<name><surname>Fifer</surname><given-names>MA</given-names></name>
<name><surname>Wruight</surname><given-names>RF</given-names></name><etal/>
</person-group>. <article-title>Positive inotropic and vasodilator actions of milrinone in patients with severe congestive heart failure</article-title>. <source>J Clin Invest</source>. <year>1985</year>;<volume>75</volume>:<fpage>643</fpage>-<lpage>649</lpage>.</citation>
</ref>
<ref id="bibr44-1089253211434966">
<label>44.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pattison</surname><given-names>A</given-names></name>
<name><surname>Astley</surname><given-names>N</given-names></name>
<name><surname>Eason</surname><given-names>CT</given-names></name>
<name><surname>Bonner</surname><given-names>FW</given-names></name>
</person-group>. <article-title>A comparison of the effects of three positive inotropic agents (amrinone, milrinone and medorinone) on platelet aggregation in human whole blood</article-title>. <source>Thromb Res</source>. <year>1990</year>;<volume>57</volume>:<fpage>909</fpage>-<lpage>918</lpage>.</citation>
</ref>
<ref id="bibr45-1089253211434966">
<label>45.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kikura</surname><given-names>M</given-names></name>
<name><surname>Kazama</surname><given-names>T</given-names></name>
<name><surname>Ikeda</surname><given-names>T</given-names></name>
<name><surname>Sato</surname><given-names>S</given-names></name>
</person-group>. <article-title>Disaggregatory effects of prostaglandin E1, amrinone, and milrinone on platelet aggregation in human whole blood</article-title>. <source>Platelets</source>. <year>2000</year>;<volume>11</volume>:<fpage>446</fpage>-<lpage>458</lpage>.</citation>
</ref>
<ref id="bibr46-1089253211434966">
<label>46.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kikura</surname><given-names>M</given-names></name>
<name><surname>Lee</surname><given-names>MK</given-names></name>
<name><surname>Safon</surname><given-names>RA</given-names></name><etal/>
</person-group>. <article-title>The effects of milrinone on platelets in patients undergoing cardiac surgery</article-title>. <source>Anesth Analg</source>. <year>1995</year>;<volume>81</volume>:<fpage>44</fpage>-<lpage>48</lpage>.</citation>
</ref>
<ref id="bibr47-1089253211434966">
<label>47.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Guinot</surname><given-names>P-G</given-names></name>
<name><surname>Depoix</surname><given-names>J-P</given-names></name>
<name><surname>Etchegoyen</surname><given-names>L</given-names></name><etal/>
</person-group>. <article-title>Anesthesia and perioperative management of patients undergoing transcatheter aortic valve implantation: analysis of 90 consecutive patients with focus on perioperative complications</article-title>. <source>J Cardiothorac Vasc Anesth</source>. <year>2010</year>;<volume>24</volume>:<fpage>752</fpage>-<lpage>761</lpage>.</citation>
</ref>
<ref id="bibr48-1089253211434966">
<label>48.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mannin</surname><given-names>SC</given-names></name>
<name><surname>Brennan</surname><given-names>TJ</given-names></name>
</person-group>. <article-title>Thoracic epidural analgesia and acute pain management</article-title>. <source>Anesth Analg</source>. <year>2011</year>;<volume>115</volume>:<fpage>181</fpage>-<lpage>188</lpage>.</citation>
</ref>
<ref id="bibr49-1089253211434966">
<label>49.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Davies</surname><given-names>RG</given-names></name>
<name><surname>Myles</surname><given-names>PS</given-names></name>
<name><surname>Graham</surname><given-names>JM</given-names></name>
<etal/>
</person-group>. <collab>A comparison of the analgesic efficacy and side-effects of paravertebral vs</collab>. <article-title>epidural blockade for thoracotomy: systemic review and metaanalysis of randomized trials</article-title>. <source>Br J Anaesth</source>. <year>2006</year>;<volume>96</volume>: <fpage>418</fpage>-<lpage>426</lpage>.</citation>
</ref>
<ref id="bibr50-1089253211434966">
<label>50.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>O’Connor</surname><given-names>CJ</given-names></name>
</person-group>. <article-title>Thoracic epidural analgesia: physiologic effects and clinical applications</article-title>. <source>J Cardiothoracic Vasc Anesth</source>. <year>1993</year>;<volume>7</volume>:<fpage>595</fpage>-<lpage>609</lpage>.</citation>
</ref>
<ref id="bibr51-1089253211434966">
<label>51.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Casati</surname><given-names>A</given-names></name>
<name><surname>Alessandrini</surname><given-names>P</given-names></name>
<name><surname>Nuzzi</surname><given-names>M</given-names></name><etal/>
</person-group>. <article-title>A prospective, randomized, blinded comparison between continuous thoracic paravertebral and epidural infusion of 0.2% ropivacaine after lung resection surgery</article-title>. <source>Eur J Anaesth</source>. <year>2006</year>;<volume>23</volume>:<fpage>999</fpage>-<lpage>1004</lpage>.</citation>
</ref>
<ref id="bibr52-1089253211434966">
<label>52.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kotze</surname><given-names>A</given-names></name>
<name><surname>Scally</surname><given-names>A</given-names></name>
<name><surname>Howell</surname><given-names>S</given-names></name>
</person-group>. <article-title>Efficacy and safety of different techniques of paravertebral block for analgesia after thoracotomy: a systematic review and metaregression</article-title>. <source>Br J Anaesth</source>. <year>2009</year>;<volume>103</volume>:<fpage>626</fpage>-<lpage>636</lpage>.</citation>
</ref>
<ref id="bibr53-1089253211434966">
<label>53.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pinteric</surname><given-names>TS</given-names></name>
<name><surname>Potocnik</surname><given-names>I</given-names></name>
<name><surname>Hadzic</surname><given-names>A</given-names></name><etal/>
</person-group>. <article-title>Comparison of continuous thoracic epidural with paravertebral block on perioperative analgesia and hemodynamic stability in patients having open lung surgery</article-title>. <source>Reg Anesth Pain Med</source>. <year>2011</year>;<volume>36</volume>:<fpage>256</fpage>-<lpage>260</lpage>.</citation>
</ref>
<ref id="bibr54-1089253211434966">
<label>54.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hara</surname><given-names>K</given-names></name>
<name><surname>Sakura</surname><given-names>S</given-names></name>
<name><surname>Nomura</surname><given-names>T</given-names></name>
<name><surname>Saito</surname><given-names>Y</given-names></name>
</person-group>. <article-title>Ultrasound guided paravertebral block in breast surgery</article-title>. <source>Anaesthesia</source>. <year>2009</year>;<volume>64</volume>: <fpage>223</fpage>-<lpage>224</lpage>.</citation>
</ref>
<ref id="bibr55-1089253211434966">
<label>55.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Boezaart</surname><given-names>AP</given-names></name>
<name><surname>Lucas</surname><given-names>SD</given-names></name>
<name><surname>Elliott</surname><given-names>CE</given-names></name>
</person-group>. <article-title>Paravertebral block: cervical,thoracic, lumbar, and sacral</article-title>. <source>Curr Opin Anaesthesiol</source>. <year>2009</year>;<volume>22</volume>:<fpage>637</fpage>-<lpage>643</lpage>.</citation>
</ref>
<ref id="bibr56-1089253211434966">
<label>56.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chin</surname><given-names>KJ</given-names></name>
<name><surname>Karmaker</surname><given-names>MK</given-names></name>
<name><surname>Peng</surname><given-names>P</given-names></name>
</person-group>. <article-title>Ultrasonography of the adult thoracic and lumbar spine for central neuraxial blockade</article-title>. <source>Anesth Analg</source>. <year>2011</year>;<volume>114</volume>:<fpage>1459</fpage>-<lpage>1485</lpage>.</citation>
</ref>
<ref id="bibr57-1089253211434966">
<label>57.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cribier</surname><given-names>A</given-names></name>
<name><surname>Eltchaninoff</surname><given-names>H</given-names></name>
<name><surname>Tron</surname><given-names>C</given-names></name><etal/>
</person-group>. <article-title>Percutaneous implantation of aortic valve prosthesis in patients with calcific aortic stenosis</article-title>. <source>J Interv Cardiol</source>. <year>2006</year>;<volume>19</volume>:<fpage>S87</fpage>-<lpage>S96</lpage>.</citation>
</ref>
<ref id="bibr58-1089253211434966">
<label>58.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Grube</surname><given-names>E</given-names></name>
<name><surname>Schuler</surname><given-names>G</given-names></name>
<name><surname>Buellesfeld</surname><given-names>L</given-names></name><etal/>
</person-group>. <article-title>Percutaneous aortic valve replacement for severe aortic stenosis in high-risk patients using the second- and third-generation self-expanding CoreValve prosthesis</article-title>. <source>J Am Coll Cardiol</source>. <year>2007</year>;<volume>50</volume>:<fpage>69</fpage>-<lpage>76</lpage>.</citation>
</ref>
<ref id="bibr59-1089253211434966">
<label>59.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Walther</surname><given-names>T</given-names></name>
<name><surname>Schuler</surname><given-names>G</given-names></name>
<name><surname>Borger</surname><given-names>MA</given-names></name><etal/>
</person-group>. <article-title>Transapical aortic valve implantation in 100 consecutive patients: comparison to propensity-matched conventional aortic valve replacement</article-title>. <source>Eur Heart J</source>. <year>2010</year>;<volume>31</volume>:<fpage>1398</fpage>-<lpage>1403</lpage>.</citation>
</ref>
<ref id="bibr60-1089253211434966">
<label>60.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Grube</surname><given-names>E</given-names></name>
<name><surname>Buellesfeld</surname></name>
<name><surname>Mueller</surname><given-names>R</given-names></name><etal/>
</person-group>. <article-title>Progress and current status of percutaneous aortic valve replacement: results of three device generations of the CoreValve Revalving System</article-title>. <source>Circ Cardiovasc Interv</source>. <year>2008</year>;<volume>1</volume>:<fpage>167</fpage>-<lpage>175</lpage>.</citation>
</ref>
<ref id="bibr61-1089253211434966">
<label>61.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Leon</surname><given-names>MB</given-names></name>
<name><surname>Smith</surname><given-names>CR</given-names></name>
<name><surname>Mack</surname><given-names>M</given-names></name><etal/>
</person-group>. <article-title>Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery</article-title>. <source>N Engl J Med</source>. <year>2010</year>;<volume>363</volume>:<fpage>1597</fpage>-<lpage>1607</lpage>.</citation>
</ref>
<ref id="bibr62-1089253211434966">
<label>62.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bosmans</surname><given-names>JM</given-names></name>
<name><surname>Kefer</surname><given-names>J</given-names></name>
<name><surname>De Bruyne</surname><given-names>B</given-names></name><etal/>
</person-group>. <article-title>Procedural, 30-day and one-year outcome following CoreValve or Edwards transcatheter aortic valve implantation: results of the Belgian national registry</article-title>. <source>Interact Cardiovasc Thorac Surg</source>. <year>2011</year>;<volume>12</volume>:<fpage>762</fpage>-<lpage>767</lpage>.</citation>
</ref>
<ref id="bibr63-1089253211434966">
<label>63.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Thomas</surname><given-names>M</given-names></name>
<name><surname>Schymik</surname><given-names>G</given-names></name>
<name><surname>Walther</surname><given-names>T</given-names></name><etal/>
</person-group>. <article-title>Thirty-day results of the SAPIEN Aortic Bioprosthesis European Outcome (SOURCE) registry: a European registry of transcatheter aortic valve implantation using the Edwards SAPIEN valve</article-title>. <source>Circulation</source>. <year>2010</year>;<volume>122</volume>:<fpage>62</fpage>-<lpage>69</lpage>.</citation>
</ref>
<ref id="bibr64-1089253211434966">
<label>64.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Buellesfeld</surname><given-names>L</given-names></name>
<name><surname>Gerckens</surname><given-names>U</given-names></name>
<name><surname>Schuler</surname><given-names>G</given-names></name><etal/>
</person-group>. <article-title>Two-year follow-up of patients undergoing transcatheter aortic valve implantation using a self-expanding valve prosthesis</article-title>. <source>J Am Coll Cardiol</source>. <year>2011</year>;<volume>57</volume>:<fpage>1650</fpage>-<lpage>1657</lpage>.</citation>
</ref>
<ref id="bibr65-1089253211434966">
<label>65.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Figulla</surname><given-names>L</given-names></name>
<name><surname>Neumann</surname><given-names>A</given-names></name>
<name><surname>Figulla</surname><given-names>HR</given-names></name><etal/>
</person-group>. <article-title>Transcatheter aortic valve implantation: evidence on safety and efficacy compared with medical therapy: a systematic review of current literature</article-title>. <source>Clin Res Cardiol</source>. <year>2011</year>;<volume>100</volume>:<fpage>265</fpage>-<lpage>276</lpage>.</citation>
</ref>
<ref id="bibr66-1089253211434966">
<label>66.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gotzmann</surname><given-names>M</given-names></name>
<name><surname>Bojara</surname><given-names>W</given-names></name>
<name><surname>Lindstaedt</surname><given-names>M</given-names></name><etal/>
</person-group>. <article-title>One-year results of transcatheter aortic valve implantation in severe symptomatic aortic valve stenosis</article-title>. <source>Am J Cardiol</source>. <year>2011</year>;<volume>107</volume>:<fpage>1687</fpage>-<lpage>1692</lpage>.</citation>
</ref>
<ref id="bibr67-1089253211434966">
<label>67.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Al Ali</surname><given-names>AM</given-names></name>
<name><surname>Altwegg</surname><given-names>L</given-names></name>
<name><surname>Horlick</surname><given-names>EM</given-names></name><etal/>
</person-group>. <article-title>Prevention and management of transcatheter balloon-expandable aortic valve malposition</article-title>. <source>Catheter Cardiovasc Interv</source>. <year>2008</year>;<volume>72</volume>:<fpage>573</fpage>-<lpage>578</lpage>.</citation>
</ref>
<ref id="bibr68-1089253211434966">
<label>68.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sherif</surname><given-names>MA</given-names></name>
<name><surname>Abdel-Wahab</surname><given-names>M</given-names></name>
<name><surname>Stocker</surname><given-names>B</given-names></name><etal/>
</person-group>. <article-title>Anatomic and procedural predictors of paravalvular aortic regurgitation after implantation of the Medtronic CoreValve bioprosthesis</article-title>. <source>J Am Coll Cardiol</source>. <year>2010</year>;<volume>56</volume>:<fpage>1623</fpage>-<lpage>1629</lpage>.</citation>
</ref>
<ref id="bibr69-1089253211434966">
<label>69.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rajani</surname><given-names>R</given-names></name>
<name><surname>Kakrad</surname><given-names>M</given-names></name>
<name><surname>Khawaja</surname><given-names>MZ</given-names></name><etal/>
</person-group>. <article-title>Paravalvular regurgitation one year after transcatheter aortic valve implantation</article-title>. <source>Catheter Cardiovasc Interv</source>. <year>2010</year>;<volume>75</volume>:<fpage>868</fpage>-<lpage>872</lpage>.</citation>
</ref>
<ref id="bibr70-1089253211434966">
<label>70.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stabile</surname><given-names>E</given-names></name>
<name><surname>Sorropago</surname><given-names>G</given-names></name>
<name><surname>Cota</surname><given-names>L</given-names></name><etal/>
</person-group>. <article-title>Management of percutaneous aortic valve malposition with a transapical “valve-in-valve” technique</article-title>. <source>Ann Thorac Surg</source>. <year>2010</year>;<volume>89</volume>:<fpage>e19</fpage>-<lpage>e21</lpage>.</citation>
</ref>
<ref id="bibr71-1089253211434966">
<label>71.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tay</surname><given-names>EL</given-names></name>
<name><surname>Gurvitch</surname><given-names>R</given-names></name>
<name><surname>Wijeysinghe</surname><given-names>N</given-names></name><etal/>
</person-group>. <article-title>Outcome of patients after transcatheter aortic valve embolization</article-title>. <source>JACC Cardiovasc Interv</source>. <year>2011</year>;<volume>4</volume>:<fpage>228</fpage>-<lpage>234</lpage>.</citation>
</ref>
<ref id="bibr72-1089253211434966">
<label>72.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Astarci</surname><given-names>P</given-names></name>
<name><surname>Desiron</surname><given-names>Q</given-names></name>
<name><surname>Glineur</surname><given-names>D</given-names></name>
<name><surname>El Khoury</surname><given-names>G</given-names></name>
</person-group>. <article-title>Transapical explantation of an embolized transcatheter valve</article-title>. <source>Interact Cardiovasc Thorac Surg</source>. <year>2011</year>;<volume>13</volume>:<fpage>1</fpage>-<lpage>2</lpage>.</citation>
</ref>
<ref id="bibr73-1089253211434966">
<label>73.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kahlert</surname><given-names>P</given-names></name>
<name><surname>Knipp</surname><given-names>SC</given-names></name>
<name><surname>Schlamann</surname><given-names>M</given-names></name><etal/>
</person-group>. <article-title>Silent and apparent cerebral ischemia after percutaneous transfemoral aortic valve implantation</article-title>. <source>Circulation</source>. <year>2010</year>;<volume>121</volume>:<fpage>870</fpage>-<lpage>878</lpage>.</citation>
</ref>
<ref id="bibr74-1089253211434966">
<label>74.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rodes-Cabau</surname><given-names>J</given-names></name>
<name><surname>Dumont</surname><given-names>E</given-names></name>
<name><surname>Boone</surname><given-names>RH</given-names></name><etal/>
</person-group>. <article-title>Cerebral embolism following transcatheter aortic valve implantation: comparison of transfemoral and transapical approaches</article-title>. <source>J Am Coll Cardiol</source>. <year>2011</year>;<volume>57</volume>:<fpage>18</fpage>-<lpage>28</lpage>.</citation>
</ref>
<ref id="bibr75-1089253211434966">
<label>75.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Arnold</surname><given-names>M</given-names></name>
<name><surname>Schulz-Heise</surname><given-names>S</given-names></name>
<name><surname>Achenbach</surname><given-names>S</given-names></name><etal/>
</person-group>. <article-title>Embolic cerebral insults after transapical aortic valve implantation detected by magnetic resonance imaging</article-title>. <source>JACC Cardiovasc Interv</source>. <year>2002</year>;<volume>3</volume>:<fpage>1126</fpage>-<lpage>1132</lpage>.</citation>
</ref>
<ref id="bibr76-1089253211434966">
<label>76.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Erkapic</surname><given-names>D</given-names></name>
<name><surname>Kim</surname><given-names>WK</given-names></name>
<name><surname>Weber</surname><given-names>M</given-names></name><etal/>
</person-group>. <article-title>Electrocardiographic and further predictors for permanent pacemaker requirement after transcatheter aortic valve implantation</article-title>. <source>Europace</source>. <year>2010</year>;<volume>12</volume>:<fpage>1188</fpage>-<lpage>1190</lpage>.</citation>
</ref>
<ref id="bibr77-1089253211434966">
<label>77.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jilaihawi</surname><given-names>H</given-names></name>
<name><surname>Chin</surname><given-names>D</given-names></name>
<name><surname>Vasa-Nicotera</surname><given-names>M</given-names></name><etal/>
</person-group>. <article-title>Predictors for permanent pacemaker requirement after transcatheter aortic valve implantation with the CoreValve bioprosthesis</article-title>. <source>Am Heart J</source>. <year>2009</year>;<volume>157</volume>:<fpage>860</fpage>-<lpage>866</lpage>.</citation>
</ref>
<ref id="bibr78-1089253211434966">
<label>78.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Roten</surname><given-names>L</given-names></name>
<name><surname>Wenaweser</surname><given-names>P</given-names></name>
<name><surname>Delacreatz</surname><given-names>E</given-names></name><etal/>
</person-group>. <article-title>Incidence and predictors of atrioventricular conduction impairment after transcatheter aortic valve implantation</article-title>. <source>Am J Cardiol</source>. <year>2010</year>;<volume>106</volume>:<fpage>1473</fpage>-<lpage>1480</lpage>.</citation>
</ref>
<ref id="bibr79-1089253211434966">
<label>79.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fraccaro</surname><given-names>C</given-names></name>
<name><surname>Buja</surname><given-names>G</given-names></name>
<name><surname>Tarantini</surname><given-names>G</given-names></name><etal/>
</person-group>. <article-title>Incidence, predictors, and outcome of conduction disorders after transcatheter self-expandable aortic valve implantation</article-title>. <source>Am J Cardiol</source>. <year>2011</year>;<volume>107</volume>:<fpage>747</fpage>-<lpage>754</lpage>.</citation>
</ref>
<ref id="bibr80-1089253211434966">
<label>80.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tzikas</surname><given-names>A</given-names></name>
<name><surname>van Dalen</surname><given-names>BM</given-names></name>
<name><surname>Van Mieghem</surname><given-names>NM</given-names></name><etal/>
</person-group>. <article-title>Frequency of conduction abnormalities after transcatheter aortic valve implantation with the Medtronic-CoreValve and the effect on left ventricular ejection fraction</article-title>. <source>Am J Cardiol</source>. <year>2011</year>;<volume>107</volume>:<fpage>285</fpage>-<lpage>289</lpage>.</citation>
</ref>
<ref id="bibr81-1089253211434966">
<label>81.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Matthews</surname><given-names>IG</given-names></name>
<name><surname>Fazal</surname><given-names>IA</given-names></name>
<name><surname>Bates</surname><given-names>MGD</given-names></name>
<name><surname>Turley</surname><given-names>AJ</given-names></name>
</person-group>. <article-title>In patients undergoing aortic valve replacement, what factors predict the requirements for permanent pacemaker implantation?</article-title> <source>Interact Cardiovasc Thorac Surg</source>. <year>2011</year>;<volume>12</volume>:<fpage>475</fpage>-<lpage>479</lpage>.</citation>
</ref>
<ref id="bibr82-1089253211434966">
<label>82.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Edwards</surname><given-names>F</given-names></name>
<name><surname>Peterson</surname><given-names>E</given-names></name>
<name><surname>Coombs</surname><given-names>L</given-names></name><etal/>
</person-group>. <article-title>Prediction of operative mortality after valve replacement surgery</article-title>. <source>J Am Coll Cardiol</source>. <year>2001</year>;<volume>37</volume>:<fpage>885</fpage>-<lpage>892</lpage>.</citation>
</ref>
<ref id="bibr83-1089253211434966">
<label>83.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wijeysundera</surname><given-names>DN</given-names></name>
<name><surname>Karkouti</surname><given-names>K</given-names></name>
<name><surname>Beattie</surname><given-names>WS</given-names></name><etal/>
</person-group>. <article-title>Improving the identification of patients at risk of postoperative renal failure after cardiac surgery</article-title>. <source>Anesthesiology</source>. <year>2006</year>;<volume>104</volume>:<fpage>65</fpage>-<lpage>72</lpage>.</citation>
</ref>
<ref id="bibr84-1089253211434966">
<label>84.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lassnigg</surname><given-names>A</given-names></name>
<name><surname>Schmidlin</surname><given-names>D</given-names></name>
<name><surname>Mouhieddine</surname><given-names>M</given-names></name><etal/>
</person-group>. <article-title>Minimal changes of serum creatinine predict prognosis in patients after cardiothoracic surgery: a prospective cohort study</article-title>. <source>J Am Soc Nephrol</source>. <year>2004</year>;<volume>15</volume>:<fpage>1597</fpage>-<lpage>1605</lpage>.</citation>
</ref>
<ref id="bibr85-1089253211434966">
<label>85.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chertow</surname><given-names>GM</given-names></name>
<name><surname>Levy</surname><given-names>EM</given-names></name>
<name><surname>Hammermeister</surname><given-names>KE</given-names></name><etal/>
</person-group>. <article-title>Independent association between acute renal failure and mortality following cardiac surgery</article-title>. <source>Am J Med</source>. <year>1998</year>;<volume>104</volume>:<fpage>343</fpage>-<lpage>348</lpage>.</citation>
</ref>
<ref id="bibr86-1089253211434966">
<label>86.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kuitunen</surname><given-names>A</given-names></name>
<name><surname>Vento</surname><given-names>A</given-names></name>
<name><surname>Suojaranta-Ylinen</surname><given-names>R</given-names></name>
<name><surname>Pettila</surname><given-names>V</given-names></name>
</person-group>. <article-title>Acute renal failure after cardiac surgery: evaluation of the RIFLE criteria</article-title>. <source>Ann Thorac Surg</source>. <year>2006</year>;<volume>81</volume>:<fpage>542</fpage>-<lpage>546</lpage>.</citation>
</ref>
<ref id="bibr87-1089253211434966">
<label>87.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tuttle</surname><given-names>KR</given-names></name>
<name><surname>Worrall</surname><given-names>NK</given-names></name>
<name><surname>Dahlstrom</surname><given-names>LR</given-names></name><etal/>
</person-group>. <article-title>Predictors of ARF after cardiac surgical procedures</article-title>. <source>Am J Kidney Dis</source>. <year>2003</year>;<volume>41</volume>:<fpage>76</fpage>-<lpage>83</lpage>.</citation>
</ref>
<ref id="bibr88-1089253211434966">
<label>88.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nuis</surname><given-names>R-JM</given-names></name>
<name><surname>Van Mieghem</surname><given-names>NM</given-names></name>
<name><surname>Tzikas</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>Frequency, determinants, and prognostic effects of acute kidney injury and red blood cell transfusion in patients undergoing transcatheter aortic valve implantation</article-title>. <source>Catheter Cardiovasc Interv</source>. <year>2010</year>;<volume>77</volume>:<fpage>881</fpage>-<lpage>889</lpage>.</citation>
</ref>
<ref id="bibr89-1089253211434966">
<label>89.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Strauch</surname><given-names>JT</given-names></name>
<name><surname>Scherener</surname><given-names>MP</given-names></name>
<name><surname>Haldenwang</surname><given-names>PL</given-names></name><etal/>
</person-group>. <article-title>Minimally invasive transapical aortic valve implantation and the risk of acute kidney injury</article-title>. <source>Ann Thorac Surg</source>. <year>2010</year>;<volume>89</volume>:<fpage>465</fpage>-<lpage>470</lpage>.</citation>
</ref>
<ref id="bibr90-1089253211434966">
<label>90.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bagur</surname><given-names>R</given-names></name>
<name><surname>Webb</surname><given-names>JG</given-names></name>
<name><surname>Nietlispach</surname><given-names>F</given-names></name><etal/>
</person-group>. <article-title>Acute kidney injury following transcatheter aortic valve implantation: predictive factors, prognostic value, and comparison with surgical aortic valve replacement</article-title>. <source>Eur Heart J</source>. <year>2010</year>;<volume>31</volume>:<fpage>865</fpage>-<lpage>874</lpage>.</citation>
</ref>
<ref id="bibr91-1089253211434966">
<label>91.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Elhmidi</surname><given-names>Y</given-names></name>
<name><surname>Bleiziffer</surname><given-names>S</given-names></name>
<name><surname>Piazza</surname><given-names>N</given-names></name><etal/>
</person-group>. <article-title>Incidence and predictors of acute kidney injury in patients undergoing transcatheter aortic valve implantation</article-title>. <source>Am Heart J</source>. <year>2011</year>;<volume>161</volume>:<fpage>735</fpage>-<lpage>739</lpage>.</citation>
</ref>
<ref id="bibr92-1089253211434966">
<label>92.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rodes-Cabau</surname><given-names>J</given-names></name>
<name><surname>Gutierrez</surname><given-names>M</given-names></name>
<name><surname>Bagur</surname><given-names>R</given-names></name><etal/>
</person-group>. <article-title>Incidence, predictive factors, and prognostic value of myocardial injury following uncomplicated transcatheter aortic valve implantation</article-title>. <source>J Am Coll Cardiol</source>. <year>2011</year>;<volume>57</volume>:<fpage>1988</fpage>-<lpage>1999</lpage>.</citation>
</ref>
<ref id="bibr93-1089253211434966">
<label>93.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gerber</surname><given-names>RT</given-names></name>
<name><surname>Osborn</surname><given-names>M</given-names></name>
<name><surname>Mikhail</surname><given-names>GW</given-names></name>
</person-group>. <article-title>Delayed mortality from aortic dissection post transcatheter aortic valve implantation (TAVI): the tip of the iceberg</article-title>. <source>Catheter Cardiovasc Interv</source>. <year>2010</year>;<volume>76</volume>:<fpage>202</fpage>-<lpage>204</lpage>.</citation>
</ref>
<ref id="bibr94-1089253211434966">
<label>94.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hayashida</surname><given-names>K</given-names></name>
<name><surname>Lefevre</surname><given-names>T</given-names></name>
<name><surname>Chevalier</surname><given-names>B</given-names></name><etal/>
</person-group>. <article-title>Transfemoral aortic valve implantation: new criteria to predict vascular complications</article-title>. <source>JACC Cardiovasc Interv</source>. <year>2011</year>;<volume>4</volume>:<fpage>851</fpage>-<lpage>858</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>